Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
53fc683fb4dcc66c7b5f3ddbadab4fb700d7d42eae0be3c7fabe882709da5872.png
complex
<table><tr><td> </td><td colspan="2">Standard margin</td><td colspan="2">Reduced margin</td><td> </td><td> </td><td> </td></tr><tr><td>Parameter</td><td>Mean</td><td>St. Dev.</td><td>Mean</td><td>St. Dev.</td><td>Difference (Gy)</td><td>(%)</td><td>p-value</td></tr><tr><td>Max dose (Gy)</td><td>61.4</td><td>1.4</td><td>56.1</td><td>8.6</td><td>5.3</td><td>8.7%</td><td>0.014</td></tr><tr><td>Mean dose (Gy)</td><td>41.9</td><td>9.1</td><td>29.9</td><td>11.6</td><td>12.0</td><td>28.7%</td><td>&lt;0.001</td></tr><tr><td>Median dose (Gy)</td><td>45.2</td><td>17.2</td><td>27.9</td><td>15.6</td><td>17.2</td><td>38.2%</td><td>&lt;0.001</td></tr><tr><td>D2% (Gy)</td><td>59.9</td><td>5.1</td><td>53.4</td><td>12.1</td><td>6.4</td><td>10.7%</td><td>0.008</td></tr><tr><td>D20% (Gy)</td><td>57.6</td><td>8.5</td><td>46.1</td><td>16.8</td><td>11.5</td><td>20.0%</td><td>0.001</td></tr><tr><td>D40% (Gy)</td><td>49.9</td><td>14.9</td><td>36.5</td><td>19.6</td><td>13.4</td><td>26.9%</td><td>&lt;0.001</td></tr><tr><td>D60% (Gy)</td><td>32.7</td><td>13.5</td><td>18.7</td><td>10.9</td><td>14.0</td><td>42.9%</td><td>&lt;0.001</td></tr><tr><td>D80% (Gy)</td><td>27.3</td><td>12.1</td><td>15.3</td><td>10.0</td><td>12.0</td><td>44.0%</td><td>&lt;0.001</td></tr><tr><td>D98% (Gy)</td><td>20.7</td><td>9.3</td><td>11.8</td><td>7.7</td><td>8.9</td><td>42.9%</td><td>&lt;0.001</td></tr></table>
86368ec1cb1e07452ff05e37cb2e59b09581e67612b38eb06bf3aa1a96ae5f28.png
complex
<table><tr><td></td><td colspan="2">PACCE oxaliplatin cohort [43]</td><td colspan="2">CAIRO2 [47]</td></tr><tr><td></td><td colspan="2"> (<i>N</i> = 823)</td><td colspan="2">(<i>N</i> = 755)</td></tr><tr><td></td><td>Ox + Bev + Pmab</td><td>Ox + Bev</td><td>Cap, Ox + Bev + Cmab</td><td>Cap, Ox + Bev</td></tr><tr><td>Median progression-free survival (95% CI), mo</td><td>10.0 (8.9&#8211;11.0)</td><td>11.4 (10.5&#8211;11.9)</td><td>9.4 (8.4&#8211;10.5)</td><td>10.7 (9.7&#8211;12.3)</td></tr><tr><td>Progression-free survival events, <i>n</i> (%)</td><td>246 (60)</td><td>221 (54)</td><td>316 (84)</td><td>293 (78)</td></tr><tr><td>Overall response rate, %*</td><td>46</td><td>48</td><td>50.0</td><td>52.7</td></tr><tr><td>Median overall survival (95% CI), mo</td><td>19.4 (18.4&#8211;20.8)</td><td>24.5 (20.4&#8211;24.5)</td><td>20.3 (17.8&#8211;24.7)</td><td>19.4 (17.5&#8211;21.4)</td></tr><tr><td>Deaths, <i>n</i> (%)</td><td>143 (35)</td><td>108 (26)</td><td>214 (57)</td><td>193 (51)</td></tr></table>
3c6b6819c2c86dbcde79f00f776a2091c9f0979cac55918e4cc013896e399568.png
complex
<table><tr><td>Name</td><td>Sequence</td><td>Description</td></tr><tr><td><i>NIP5;1_qRT-PCR-1</i></td><td>caccgattttccctctcctgat</td><td rowspan="10">Probes for realtime PCR</td></tr><tr><td><i>NIP5;1_qRT-PCR-2</i></td><td>ctctttcttactctctagcctc</td></tr><tr><td><i>NIP5;1_qRT-PCR-3</i></td><td>gaatgttcccacgaactcgg</td></tr><tr><td><i>NIP5;1_qRT-PCR-4</i></td><td>acattcatcttgatattcacc</td></tr><tr><td><i>NIP5;1_qRT-PCR-5</i></td><td>gcatgcagcgttaccgatta</td></tr><tr><td><i>PP2A_qRT-PCR-1</i></td><td>ccatgtttgaggatcttacgc</td></tr><tr><td><i>PP2A_qRT-PCR-2</i></td><td>tgtctacatctcagcttcagtgtc</td></tr><tr><td><i>PP2A_qRT-PCR-3</i></td><td>gctccaacaatttcccaaga</td></tr><tr><td><i>PP2A_qRT-PCR-4</i></td><td>caagattcggttagattattg</td></tr><tr><td><i>PP2A_qRT-PCR-5</i></td><td>gcgagaaattgacaatcacag</td></tr><tr><td><i>NIP5;1_mRNA_F</i></td><td>atttaggtgacactatagtaagctcaaagactaaccaaac</td><td rowspan="4">For amplification of the standard DNA fragments</td></tr><tr><td><i>NIP5;1_mRNA_R</i></td><td>ttacacatgccatagattttat</td></tr><tr><td><i>PP2A_mRNA_F</i></td><td>atttaggtgacactatagcggtctcatttctcgttcttc</td></tr><tr><td><i>PP2A_mRNA_R</i></td><td>cacttgataagtaaattatttg</td></tr></table>
6cf2b3a4f5e9b1e3668d41787799866e33baea85ee3398544f79d2f6d1b52da8.png
simple
<table><tr><td>sCr (mg/dl)</td><td>AKI group</td><td>non-AKI group</td><td><i>P</i> value</td></tr><tr><td></td><td>(<i>n</i> = 11)</td><td>(<i>n</i> = 39)</td><td></td></tr><tr><td>Preoperative</td><td>0.72 &#177; 0.14</td><td>0.68 &#177; 0.15</td><td>0.531</td></tr><tr><td>Postoperative</td><td></td><td></td><td></td></tr><tr><td>1 day</td><td>0.83 &#177; 0.11</td><td>0.69 &#177; 0.16</td><td>&lt;0.05</td></tr><tr><td>Postoperative</td><td></td><td></td><td></td></tr><tr><td>2 days</td><td>1.04 &#177; 0.15</td><td>0.78 &#177; 0.19</td><td>&lt;0.01</td></tr><tr><td>Postoperative</td><td></td><td></td><td></td></tr><tr><td>3 days</td><td>1.05 &#177; 0.12</td><td>0.77 &#177; 0.18</td><td>&lt;0.01</td></tr></table>
782b33f1060d8206fde9e0d3df4f2b0cb56713f56ea20830ea3a3ca267a45e06.png
complex
<table><tr><td colspan="2">Germplasm or genotypes</td><td>Sites (No)</td><td>Reference</td></tr><tr><td>Type</td><td>Number</td><td></td><td></td></tr><tr><td>Natural accession</td><td>124</td><td>1</td><td>Mengesha et al. (1965)</td></tr><tr><td>Hybrids</td><td>559</td><td>1</td><td>Berhe et al. (1989a,b,c)</td></tr><tr><td>Natural accession</td><td>21</td><td></td><td>Bekele (1996)</td></tr><tr><td>Natural accession</td><td>225</td><td></td><td>Ketema (1993)</td></tr><tr><td>RIL (key Murri &#215; Fesho)</td><td>165</td><td>3</td><td>Tefera et al. (2003b)</td></tr><tr><td>RIL (key Murri &#215;<i>E. pilosa</i>)</td><td>200</td><td>3</td><td>Tefera et al. (2003a)</td></tr><tr><td>F<sub>2</sub> (12 crosses)</td><td>12</td><td>1</td><td>Tefera et al. (2008)</td></tr><tr><td>Natural accession</td><td>320</td><td>2</td><td>Assefa et al. (1999, 2000)</td></tr><tr><td>Natural accession</td><td>120</td><td>4</td><td>Assefa et al. (2001b)</td></tr><tr><td>Natural accession</td><td>1080</td><td>1</td><td>Assefa et al. (2001a)</td></tr><tr><td>Natural accession</td><td>3000</td><td>1</td><td>Assefa et al. (2002a,b, 2003b)</td></tr><tr><td>Natural accession</td><td>3600</td><td>1</td><td>Kefyalew et al. (2000)</td></tr><tr><td>Natural accession</td><td>144</td><td>2</td><td>Adnew et al. (2005)</td></tr><tr><td>RIL (196 &#215; 974)</td><td>196</td><td>2</td><td>Chanyalew et al. (2006)</td></tr><tr><td>RIL (196 &#215; 2356)</td><td>190</td><td>2</td><td>Chanyalew et al. (2009)</td></tr><tr><td>RIL (Kay Murri &#215;<i>E. pilosa</i>)</td><td>94</td><td>3</td><td>Yu et al. (2007)</td></tr><tr><td>Natural accession</td><td>37</td><td>1</td><td>Ayalew et al. (2011)</td></tr><tr><td>Natural accession</td><td>15</td><td>1</td><td>Plaza-Wu&#776;thrich et al. (2013)</td></tr><tr><td>Natural accession</td><td>81</td><td>1</td><td>Lule and Mengistu (2014)</td></tr></table>
9897bcf2700a8688846a677b613d7741670bab3877d817b39c784bb3d77835e6.png
complex
<table><tr><td>Variables</td><td>Categories</td><td colspan="8">Asthma confirmed by BHR</td></tr><tr><td></td><td></td><td colspan="4">Crude model</td><td colspan="4">Adjusted model</td></tr><tr><td></td><td></td><td>PR</td><td colspan="2">95 % CI</td><td><i>p</i> value</td><td>PR</td><td colspan="2">95 % CI</td><td><i>p</i> value</td></tr><tr><td>Group</td><td>Exposed vs Non-exposed</td><td>1.08</td><td>0.69</td><td>1.68</td><td>0.73</td><td>1.12</td><td>0.71</td><td>1.76</td><td>0.63</td></tr><tr><td>Endotoxin levels</td><td>Low vs High</td><td>1.21</td><td>0.78</td><td>1.88</td><td>0.40</td><td>0.79</td><td>0.51</td><td>1.22</td><td>0.29</td></tr><tr><td>Institutions</td><td>UNICAMP vs USP</td><td>1.40</td><td>0.89</td><td>2.18</td><td>0.14</td><td>1.25</td><td>0.81</td><td>1.93</td><td>0.31</td></tr><tr><td>Atopy</td><td>Yes vs No</td><td>7.07</td><td>3.68</td><td>13.58</td><td>&lt;0.01</td><td>6.60</td><td>3,42</td><td>12.71</td><td>&lt;0.01</td></tr><tr><td>Smoking</td><td>Yes vs No</td><td>0.89</td><td>0.48</td><td>1.64</td><td>0.70</td><td>1.00</td><td>0.54</td><td>1.86</td><td>0.99</td></tr><tr><td>Sex</td><td>Male vs Female</td><td>1.39</td><td>0.87</td><td>2.21</td><td>0.17</td><td>1.48</td><td>0.93</td><td>2.37</td><td>0.10</td></tr><tr><td>Past exposure to laboratory animals</td><td>Yes vs No</td><td>1.36</td><td>0.87</td><td>2.14</td><td>0.17</td><td>1.24</td><td>0.79</td><td>1.94</td><td>0.35</td></tr><tr><td>Pet owning history</td><td>Yes vs No</td><td>1.17</td><td>0.73</td><td>1.87</td><td>0.52</td><td>1.05</td><td>0.66</td><td>1.66</td><td>0.83</td></tr><tr><td>Age</td><td>Continuous</td><td>0.96</td><td>0.94</td><td>0.99</td><td>&lt;0.01</td><td>0.98</td><td>0.95</td><td>1.01</td><td>0.16</td></tr><tr><td rowspan="2">Worker functions</td><td>Technicians/secretaries vs researchers</td><td>1.44</td><td>0.52</td><td>3.95</td><td>0.48</td><td>1.35</td><td>0.49</td><td>3.72</td><td>0.56</td></tr><tr><td>Students vs researchers</td><td>1.74</td><td>0.65</td><td>4.71</td><td>0.27</td><td>1.09</td><td>0.41</td><td>3.72</td><td>0.56</td></tr></table>
1841538fa54707869d10914dda7789933d3772d8821dc739cd76d069ac621500.png
simple
<table><tr><td></td><td>ADHD group(<i>n </i>= 16)</td><td>Control group(<i>n </i>= 16)</td><td>Group differences<sup>a</sup></td></tr><tr><td></td><td>M (SD)</td><td>M (SD)</td><td></td></tr><tr><td>Age (years)</td><td>10.7 (1.6)</td><td>10.2 (1.3)</td><td>ns</td></tr><tr><td>IQ (WISC-III)</td><td>97.1 (14.2)</td><td>102.7 (9.5)</td><td>ns</td></tr><tr><td>CBCL (parent rating)</td><td></td><td></td><td></td></tr><tr><td>Internalizing</td><td>60.4 (7.7)</td><td>52.3 (10.7)</td><td><i>p </i>= .01</td></tr><tr><td>Externalizing</td><td>64.1 (4.8)</td><td>52.9 (6.6)</td><td><i>p </i>&lt; .001</td></tr><tr><td>Attention</td><td>71.1 (5.6)</td><td>54.4 (3.7)</td><td><i>p </i>&lt; .001</td></tr><tr><td>FBB-HKS (parent rating)</td><td>82.6 (10.4)</td><td>36.7 (18.9)</td><td><i>p </i>&lt; .001</td></tr><tr><td>FA baseline</td><td>29.0 (10.7)</td><td>30.0 (13.9)</td><td>ns</td></tr><tr><td>FA social reward</td><td>13.1 (7.3)</td><td>22.1 (10.9)</td><td><i>p </i>= .011</td></tr><tr><td>FA monetary reward</td><td>10.6 (8.5)</td><td>14.8 (10.8)</td><td>ns</td></tr><tr><td>RT hits baseline</td><td>446.3 (84.3)</td><td>435.8 (46.1)</td><td>ns</td></tr><tr><td>RT hits social reward</td><td>438.8 (88.7)</td><td>414.6 (43.2)</td><td>ns</td></tr><tr><td>RT hits monetary reward</td><td>454.4 (80.4)</td><td>416.8 (58.4)</td><td>ns</td></tr><tr><td>RT false alarms baseline</td><td>355.2 (75.5)</td><td>407.5 (134.3)</td><td>ns</td></tr><tr><td>RT false alarms social reward</td><td>396.4 (121.1)</td><td>401.3 (126.0)</td><td>ns</td></tr><tr><td>RT false alarms monetary reward</td><td>397.9 (65.9)</td><td>388.7 (164.5)</td><td>ns</td></tr></table>
8979775de6e6d790dd71d4b6ef5b196298df66bfc293f7e8dcf1b75f1f012678.png
complex
<table><tr><td>Fracture sites</td><td>No. of fractures</td><td>Fracture IR (/1000 PY)</td><td>Age/sex adjusted HR (95 % CI)</td><td>Adjusted HR (95 % CI)</td></tr><tr><td colspan="5">Major osteoporotic fracture</td></tr><tr><td> Never-GLP1-ra use<sup>a</sup></td><td>4373</td><td>6.1</td><td>Reference</td><td>Reference</td></tr><tr><td> Current GLP1-ra use</td><td>44</td><td>3.7</td><td>0.97 (0.71&#8211;1.31)</td><td>0.97 (0.72&#8211;1.32)<sup>b</sup></td></tr><tr><td colspan="5">Hip fracture</td></tr><tr><td> Never-GLP1-ra use<sup>a</sup></td><td>1383</td><td>1.9</td><td>Reference</td><td>Reference</td></tr><tr><td> Current GLP1-ra use</td><td>2</td><td>0.2</td><td>0.26 (0.06&#8211;1.03)</td><td>0.27 (0.07&#8211;1.08)<sup>c</sup></td></tr><tr><td colspan="5">Radius/ulna fracture</td></tr><tr><td> Never-GLP1-ra use<sup>a</sup></td><td>1442</td><td>2.0</td><td>Reference</td><td>Reference</td></tr><tr><td> Current GLP1-ra use</td><td>15</td><td>1.3</td><td>1.78 (0.47&#8211;1.32)</td><td>0.82 (0.48&#8211;1.37)<sup>d</sup></td></tr><tr><td colspan="5">Vertebral fracture</td></tr><tr><td> Never-GLP1-ra use<sup>a</sup></td><td>513</td><td>0.7</td><td>Reference</td><td>Reference</td></tr><tr><td> Current GLP1-ra use</td><td>8</td><td>0.7</td><td>1.59 (0.78&#8211;3.24)</td><td>1.64 (0.80&#8211;3.37)<sup>e</sup></td></tr></table>
de08d6f43d8f83c166735facfeeddc1b203ec5660a4a5111cd5036af9f33ee8e.png
complex
<table><tr><td></td><td></td><td></td><td colspan="3">Age</td><td colspan="3">Gender</td></tr><tr><td>EVA derivative</td><td>Intercept</td><td>R<sup>2</sup></td><td>B</td><td>&#946;</td><td>p</td><td>B</td><td>&#946;</td><td><i>p</i></td></tr><tr><td>Prolonged sitting (&gt;30 min)</td><td>&#8722;30.6</td><td>.01</td><td>0.00</td><td>0.00</td><td>1.0</td><td>4.00</td><td>0.12</td><td>.12</td></tr><tr><td>BB standing (&lt;5 min)</td><td>&#8722;1.9</td><td>.03</td><td>0.08</td><td>0.06</td><td>.44</td><td>4.15</td><td>0.16</td><td>.03</td></tr><tr><td>BB walking (&lt;5 min)</td><td>2.2</td><td>.03</td><td>0.13</td><td>0.09</td><td>.21</td><td>&#8722;4.23</td><td>&#8722;0.16</td><td>.03</td></tr><tr><td>Walking &gt;10 min</td><td>18.3</td><td>.06</td><td>0.05</td><td>0.08</td><td>.25</td><td>&#8722;2.47</td><td>&#8722;0.24</td><td>&lt;.01</td></tr></table>
7f03fe2d406922d39e89ca593beab7aea7d5b0c970e4a0d515ba19f5d9f373a9.png
simple
<table><tr><td>Accession no.</td><td>Strain</td><td>BioSample ID</td><td>BioProject ID</td></tr><tr><td>CP018252</td><td>9000</td><td>SAMN05544760</td><td>PRJNA336330</td></tr><tr><td>CP018250</td><td>10671</td><td>SAMN05544761</td><td>PRJNA336330</td></tr><tr><td>CP018247</td><td>7784</td><td>SAMN05544762</td><td>PRJNA336330</td></tr><tr><td>CP018237</td><td>155</td><td>SAMN05544764</td><td>PRJNA336330</td></tr><tr><td>CP018243</td><td>350</td><td>SAMN05544765</td><td>PRJNA336330</td></tr><tr><td>CP018239</td><td>272</td><td>SAMN05544766</td><td>PRJNA336330</td></tr><tr><td>CP018245</td><td>472</td><td>SAMN05544767</td><td>PRJNA336330</td></tr><tr><td>CP018241</td><td>319</td><td>SAMN05544768</td><td>PRJNA336330</td></tr><tr><td>CP015832</td><td>180</td><td>SAMN05007044</td><td>PRJNA321984</td></tr><tr><td>NC_002695</td><td>Sakai</td><td>na</td><td>PRJNA57781</td></tr><tr><td>NC_011353</td><td>EC4115</td><td>SAMN02603441</td><td>PRJNA224116</td></tr><tr><td>NC_013008</td><td>TW14359</td><td>SAMN02604255</td><td>PRJNA224116</td></tr><tr><td>CP008957</td><td>EDL933</td><td>SAMN02905113</td><td>PRJNA253471</td></tr><tr><td>CP010304</td><td>SS52</td><td>SAMN03265100</td><td>PRJNA201344</td></tr></table>
57c97298c16027babe6726ca2058ccf5280ec0b056394e5a0965bf569906f328.png
simple
<table><tr><td><i>n1</i></td><td><i>n2</i></td><td>Ratio</td><td>Distance</td></tr><tr><td>1</td><td>2</td><td>0.50</td><td>1</td></tr><tr><td>2</td><td>3</td><td>0.67</td><td>1</td></tr><tr><td>3</td><td>4</td><td>0.75</td><td>1</td></tr><tr><td>4</td><td>5</td><td>0.80</td><td>1</td></tr><tr><td>5</td><td>6</td><td>0.83</td><td>1</td></tr><tr><td>6</td><td>7</td><td>0.86</td><td>1</td></tr></table>
887450ae95c874b12fd0c8b2d62eb6c37698bb939773802df044dccb91c5dbe0.png
complex
<table><tr><td></td><td>Composition</td><td>Strain-to-failure (mm/mm)</td><td>Stress-at-failure (MPa)</td><td>Toughness (MJ/m<sup>3</sup>)</td></tr><tr><td rowspan="4"><i>T</i> = temperature at loss modulus peak</td><td>5% BPA</td><td>1.43 &#177; 0.0985</td><td>11.9 &#177; 2.14</td><td>8.99 &#177; 1.72</td></tr><tr><td>15% BPA</td><td>0.773 &#177; 0.0906</td><td>14.2 &#177; 1.51</td><td>6.21 &#177; 0.992</td></tr><tr><td>25% BPA</td><td>0.609 &#177; 0.119</td><td>13.2 &#177; 1.07</td><td>3.96 &#177; 0.747</td></tr><tr><td>35% BPA</td><td>0.475 &#177; 0.0957</td><td>23.0 &#177; 4.15</td><td>6.38 &#177; 1.79</td></tr><tr><td rowspan="4"><i>T</i> = temperature at tan delta peak</td><td>5% BPA</td><td>1.41 &#177; 0.254</td><td>2.75 &#177; 0.338</td><td>1.49 &#177; 0.296</td></tr><tr><td>15% BPA</td><td>0.590 &#177; 0.182</td><td>2.87 &#177; 0.254</td><td>0.697 &#177; 0.169</td></tr><tr><td>25% BPA</td><td>0.357 &#177; 0.0354</td><td>4.09 &#177; 0.251</td><td>0.647&#177;0.0723</td></tr><tr><td>35% BPA</td><td>0.376 &#177; 0.0879</td><td>7.73 &#177; 1.56</td><td>1.24 &#177; 0.316</td></tr></table>
32f0a4ccd8f3903c430f13a002d1ff86186f191c25ea70e76581f604a1f85fc6.png
simple
<table><tr><td> </td><td>PR</td><td>GR</td><td>CS</td><td>OD</td><td>IT</td><td>FL</td></tr><tr><td>PR</td><td>&#8212;</td><td>MI</td><td>WI</td><td>EI</td><td>SI</td><td>VSI</td></tr><tr><td>GR</td><td></td><td>&#8212;</td><td></td><td>SMI</td><td></td><td></td></tr><tr><td>CS</td><td></td><td>WI</td><td>&#8212;</td><td></td><td></td><td></td></tr><tr><td>OD</td><td></td><td></td><td>SI</td><td>&#8212;</td><td>WI</td><td>SI</td></tr><tr><td>IT</td><td></td><td>SMI</td><td>MI</td><td></td><td>&#8212;</td><td></td></tr><tr><td>FL</td><td></td><td>WI</td><td>EI</td><td></td><td>MI</td><td>&#8212;</td></tr></table>
d38de7789e2352444ae7437eed4a53ead45816f1b5ba7ae98058ff2a5c230de2.png
complex
<table><tr><td colspan="4">Locus</td><td colspan="5">Initial Signal</td><td colspan="5">Regional Validation Signal</td></tr><tr><td>Chr</td><td>Position (Mb)</td><td>Gene</td><td>Prior HDL or Lipid Association [Ref]</td><td>Lead SNP</td><td>MA</td><td>MAF</td><td>Effect (mg/dl)</td><td><i>P</i>-value</td><td>Lead SNP</td><td>MA</td><td>MAF</td><td>Effect (mg/dl)</td><td><i>P</i>-value</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="5">Whites</td><td colspan="5">African Americans</td></tr><tr><td>1</td><td>185.2</td><td>PLA2G4A</td><td></td><td>rs10157410</td><td>C</td><td>0.101</td><td>3.46</td><td>6.66E-05</td><td>rs4648287</td><td>G</td><td>0.049</td><td>3.21</td><td>0.0040</td></tr><tr><td>1</td><td>228.4</td><td>GALNT2</td><td>Yes [11]</td><td>rs2144300</td><td>G</td><td>0.422</td><td>-1.85</td><td>2.29E-04</td><td>rs2144297</td><td>A</td><td>0.345</td><td>-1.92</td><td>0.0233</td></tr><tr><td>7</td><td>38.2</td><td>STARD3NL</td><td>Yes [28]</td><td>rs10240718</td><td>A</td><td>0.078</td><td>3.23</td><td>3.98E-04</td><td>rs7795499</td><td>A</td><td>0.329</td><td>1.76</td><td>0.0350</td></tr><tr><td>11</td><td>68.0</td><td>LRP5</td><td>Yes [27]</td><td>rs3736228</td><td>A</td><td>0.136</td><td>2.64</td><td>5.07E-04</td><td>rs4988331</td><td>A</td><td>0.168</td><td>2.12</td><td>0.0281</td></tr><tr><td>13</td><td>77.4</td><td>EDNRB</td><td></td><td>rs3818416</td><td>A</td><td>0.241</td><td>2.21</td><td>2.97E-04</td><td>rs3818416</td><td>A</td><td>0.329</td><td>-2.24</td><td>0.0028</td></tr><tr><td>15</td><td>56.6</td><td>LIPC</td><td>Yes [11]</td><td>rs9652472</td><td>G</td><td>0.041</td><td>-4.40</td><td>6.02E-04</td><td>rs10518978</td><td>A</td><td>0.123</td><td>-3.01</td><td>0.0101</td></tr><tr><td>16</td><td>65.5</td><td>CDH16</td><td></td><td>rs3743725</td><td>A</td><td>0.030</td><td>5.23</td><td>7.51E-04</td><td>rs13336470</td><td>A</td><td>0.322</td><td>2.63</td><td>0.0041</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="5">African Americans</td><td colspan="5">Whites</td></tr><tr><td>4</td><td>57.5</td><td>REST</td><td></td><td>rs6847086</td><td>A</td><td>0.461</td><td>2.67</td><td>7.14E-04</td><td>rs4109037</td><td>A</td><td>0.136</td><td>2.33</td><td>0.0025</td></tr><tr><td>6</td><td>152.5</td><td>ESR1</td><td>Yes [29]</td><td>rs3020384</td><td>C</td><td>0.487</td><td>2.65</td><td>7.63E-04</td><td>rs12199198</td><td>C</td><td>0.067</td><td>-2.07</td><td>0.0372</td></tr><tr><td>7</td><td>87.1</td><td>ABCB1</td><td>Yes [26]</td><td>rs3213619</td><td>G</td><td>0.072</td><td>5.22</td><td>2.74E-04</td><td>rs10267099</td><td>G</td><td>0.220</td><td>1.62</td><td>0.0059</td></tr><tr><td>8</td><td>10.1</td><td>MSRA</td><td></td><td>rs2975721</td><td>T</td><td>0.385</td><td>2.74</td><td>4.69E-04</td><td>rs6601419</td><td>A</td><td>0.338</td><td>1.66</td><td>0.0029</td></tr><tr><td>13</td><td>94.5</td><td>ABCC4</td><td></td><td>rs7319001</td><td>A</td><td>0.095</td><td>4.92</td><td>5.39E-04</td><td>rs1189470</td><td>C</td><td>0.154</td><td>2.12</td><td>0.0036</td></tr><tr><td>16</td><td>52.4</td><td>FTO</td><td>Yes [25]</td><td>rs12595985</td><td>A</td><td>0.109</td><td>4.52</td><td>2.90E-04</td><td>rs9940629</td><td>A</td><td>0.448</td><td>1.56</td><td>0.0041</td></tr></table>
6ad8352aa5c400319828fa0956916c73cbc27e4ebcb55e665653a5c0ad8e2bb8.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">TNF-&#945; Stimulation (U/ml)</td></tr><tr><td>0</td><td>10</td><td>100</td></tr><tr><td>HUVECs in monocultures</td><td>4.9 &#177; 1.5</td><td>15.7 &#177; 0.8*</td><td>24.57 &#177; 3.01**</td></tr><tr><td>HUVECs in direct contact with podocytes</td><td>11.43 &#177; 4.7</td><td>21.53 &#177; 5.7</td><td>38.7 &#177; 9.8*</td></tr><tr><td>HUVECs with no direct contact</td><td>5.7 &#177; 1.13</td><td>14.5 &#177; 1.9*</td><td>24.01 &#177; 1.6**</td></tr></table>
7dbd474ee782708a0fa7a54b85612aa415b66230d541f52c19746576350baa36.png
complex
<table><tr><td rowspan="2"></td><td>MD</td><td>Normal LV and RV function</td><td>Impaired LV and/or RV function</td><td rowspan="2"><i>p</i> value</td></tr><tr><td><i>N</i> = 63</td><td><i>N</i> = 31</td><td><i>N</i> = 32</td></tr><tr><td>Male, <i>n</i> (%)</td><td>63 (100)</td><td>31 (100)</td><td>32 (100)</td><td>1.00</td></tr><tr><td>Age, years</td><td>31 &#177; 15</td><td>27 &#177; 15</td><td>34 &#177; 15</td><td>0.11</td></tr><tr><td>BMD, <i>n</i> (%)</td><td>51 (81)</td><td>26 (84)</td><td>25 (78)</td><td>0.75</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>24 &#177; 4</td><td>24 &#177; 5</td><td>24 &#177; 3</td><td>0.72</td></tr><tr><td>Skeletal muscle status 0/1/2/3, <i>n</i> (%)</td><td>2 (3)/43 (68)/13 (21)/5 (8)</td><td>2 (7)/23 (74)/5 (16)/1 (3)</td><td>20 (63)/8 (25)/4 (13)/0 (0)</td><td>0.20</td></tr><tr><td>ACE inhibitor, <i>n</i> (%)</td><td>16 (25)</td><td>2 (7)</td><td>14 (44)</td><td>0.001</td></tr><tr><td>Beta-blocker, <i>n</i> (%)</td><td>14 (22)</td><td>4 (13)</td><td>10 (31)</td><td>0.13</td></tr><tr><td>CK, U/L</td><td>1226 (653&#8211;2424)</td><td>1250 (652&#8211;3043)</td><td>1221 (727&#8211;2291)</td><td>0.86</td></tr><tr><td>Elevated hs-Trop, <i>n</i> (%)<sup>a</sup></td><td>30 (48)</td><td>8 (26)</td><td>22 (67)</td><td>0.001</td></tr><tr><td>Elevated NT-proBNP, <i>n</i> (%)<sup>b</sup></td><td>3 (5)</td><td>0 (0)</td><td>3 (9)</td><td>0.24</td></tr></table>
7e5f9992fc1f71c6cc754bb75cf545e80ead3275ec53f95e57d3423ff2de9a27.png
simple
<table><tr><td>Plasmid</td><td>Description</td><td>Source of reference</td></tr><tr><td>pGK423</td><td>Yeast expression vector containing <i>PGK1</i> promoter, 2 &#956; origin, <i>HIS3</i> marker, no expression (control plasmid)</td><td>Ishii et al. [10]</td></tr><tr><td>pGK426</td><td>Yeast expression vector containing <i>PGK1</i> promoter, 2 &#956; origin, <i>URA3</i> marker, no expression (control plasmid)</td><td>Ishii et al. [10]</td></tr><tr><td>pGK406</td><td>Yeast integration vector containing <i>PGK1</i> promoter, <i>URA3</i> maker</td><td>Ishii et al. [10]</td></tr><tr><td>pATP425</td><td>Yeast three gene expression vector containing <i>ADH1</i>, <i>TDH3</i>, and <i>PGK1</i> promoters, 2 &#956; origin, <i>LEU2</i> marker, no expression (control plasmid)</td><td></td></tr><tr><td>pATP424</td><td>Yeast three gene expression vector containing <i>ADH1</i>, <i>TDH3</i> and <i>PGK1</i> promoters, 2 &#956; origin, <i>TRP1</i> marker, no expression (control plasmid)</td><td></td></tr><tr><td>pATP423</td><td>Yeast three gene expression vector containing <i>ADH1</i>, <i>TDH3</i> and <i>PGK1</i> promoters, 2 &#956; origin, <i>HIS3</i> marker, no expression (control plasmid)</td><td></td></tr><tr><td>pGK423-<i>kivd</i></td><td><i>HIS3</i>, expression of <i>L. lactis kivd</i> gene</td><td>Kondo et al. [14]</td></tr><tr><td>pGK423-<i>ARO10</i></td><td><i>HIS3</i>, expression of <i>S. cerevisiae ARO10</i> gene</td><td>Kondo et al. [14]</td></tr><tr><td>pGK423-<i>THI3</i></td><td><i>HIS3</i>, expression of <i>S. cerevisiae THI3</i> gene</td><td>Kondo et al. [14]</td></tr><tr><td>pGK426-<i>ADH1</i></td><td><i>URA3</i>, expression of <i>S. cerevisiae ADH1</i> gene</td><td>Kondo et al. [14]</td></tr><tr><td>pGK426-<i>ADH2</i></td><td><i>URA3</i>, expression of <i>S. cerevisiae ADH2</i> gene</td><td>Kondo et al. [14]</td></tr><tr><td>pGK426-<i>ADH5</i></td><td><i>URA3</i>, expression of <i>S. cerevisiae ADH5</i> gene</td><td>Kondo et al. [14]</td></tr><tr><td>pGK426-<i>ADH6</i></td><td><i>URA3</i>, expression of <i>S. cerevisiae ADH6</i> gene</td><td>Kondo et al. [14]</td></tr><tr><td>pGK426-<i>ADH7</i></td><td><i>URA3</i>, expression of <i>S. cerevisiae ADH7</i> gene</td><td>Kondo et al. [14]</td></tr><tr><td>pGK426-<i>SFA1</i></td><td><i>URA3</i>, expression of <i>S. cerevisiae SFA1</i> gene</td><td>Kondo et al. [14]</td></tr><tr><td>pGK426-<i>cimA</i></td><td><i>URA3</i>, expression of <i>M. jannaschii cimA</i> gene</td><td>This study</td></tr><tr><td>pGK406-<i>cimA</i></td><td><i>URA3</i>, genomic integration of <i>M. jannaschii cimA</i> gene</td><td>This study</td></tr><tr><td>pATP425-<i>leuC</i>(Cb)-<i>leuD</i>(Cb)</td><td><i>LEU2</i>, co-expression of <i>C. beijerinckii leuC</i> and <i>leuD</i> genes</td><td>This study</td></tr><tr><td>pATP425-<i>leuC</i>(Ec)-<i>leuD</i>(Ec)</td><td><i>LEU2</i>, co-expression of <i>E. coli leuC</i> and <i>leuD</i> genes</td><td>This study</td></tr><tr><td>pATP425-<i>leuC</i>(Mj)-<i>leuD</i>(Mj)</td><td><i>LEU2</i>, co-expression of <i>M. jannaschii leuC</i> and <i>leuD</i> genes</td><td>This study</td></tr><tr><td>pATP425-<i>cimA</i>-<i>leuC</i>(Cb)-<i>leuD</i>(Cb)</td><td><i>LEU2</i>, co-expression of <i>M. jannaschii cimA</i>, <i>C. beijerinckii leuC</i> and <i>leuD</i> genes</td><td>This study</td></tr><tr><td>pATP425-<i>cimA</i>-<i>leuC</i>(Ec)-<i>leuD</i>(Ec)</td><td><i>LEU2</i>, co-expression of <i>M. jannaschii cimA</i>, <i>E. coli leuC</i> and <i>leuD</i> genes</td><td>This study</td></tr><tr><td>pATP425-<i>cimA</i>-<i>leuC</i>(Mj)-<i>leuD</i>(Mj)</td><td><i>LEU2</i>, co-expression of <i>M. jannaschii cimA</i>, <i>leuC</i> and <i>leuD</i> genes</td><td>This study</td></tr><tr><td>pATP424-<i>ILV1</i></td><td><i>TRP1</i>, expression of <i>S. cerevisiae ILV1</i> gene</td><td>This study</td></tr><tr><td>pATP424-<i>tdcB</i></td><td><i>TRP1</i>, expression of <i>E. coli tdcB</i> gene</td><td>This study</td></tr><tr><td>pATP424-<i>ilvA</i></td><td><i>TRP1</i>, expression of <i>E. coli ilvA</i> gene</td><td>This study</td></tr><tr><td>pATP424-<i>tdcB</i>-<i>asd</i></td><td><i>TRP1</i>, co-expression of <i>E. coli tdcB</i> and <i>asd</i> genes</td><td>This study</td></tr><tr><td>pATP423-<i>thrA</i>-<i>thrB</i>-<i>thrC</i></td><td><i>HIS3</i>, co-expression of <i>E. coli thrA</i>, <i>thrB</i> and <i>thrC</i> genes</td><td>This study</td></tr></table>
fb958939ba8537f80aa5dc16bc69e997351c132bbf943b504a6fd8e5382e121b.png
simple
<table><tr><td>Source</td><td>Type III sum of squares</td><td>df</td><td>mean square</td><td>F</td><td>P</td></tr><tr><td>population</td><td>33.571</td><td>1</td><td>33.571</td><td>98.623</td><td>&lt; 0.001</td></tr><tr><td>sex</td><td>12.560</td><td>1</td><td>12.560</td><td>36.899</td><td>&lt; 0.001</td></tr><tr><td>population*sex</td><td>3.830</td><td>1</td><td>3.830</td><td>11.251</td><td>= 0.001</td></tr><tr><td>flower diameter</td><td>0.104</td><td>1</td><td>0.104</td><td>0.304</td><td>= 0.581</td></tr><tr><td>error</td><td>187.217</td><td>550</td><td>0.337</td><td></td><td></td></tr></table>
ddc1e05c6f99fb473c7f8ad9f4a99734d3b2618d98ed35a74c32f908f287d6cf.png
complex
<table><tr><td>Antibody(ies)</td><td>Number of patients</td><td>Percentage</td></tr><tr><td colspan="3">Alloantibodies</td></tr><tr><td>Anti-c</td><td>10</td><td>6.4</td></tr><tr><td>Anti-C</td><td>3</td><td>1.9</td></tr><tr><td>Anti-c and anti-E</td><td>10</td><td>6.4</td></tr><tr><td>Anti-C + D</td><td>8</td><td>5.1</td></tr><tr><td>Anti-C + D + E</td><td>1</td><td>0.6</td></tr><tr><td>Anti-D</td><td>25</td><td>16.0</td></tr><tr><td>Anti-e</td><td>1</td><td>0.6</td></tr><tr><td>Anti-E</td><td>57</td><td>36.3</td></tr><tr><td>Anti-Fy<sup>a</sup></td><td>1</td><td>0.6</td></tr><tr><td>Anti-Jk<sup>a</sup></td><td>3</td><td>1.9</td></tr><tr><td>Anti-K</td><td>7</td><td>4.5</td></tr><tr><td>Anti-Kp<sup>a</sup></td><td>1</td><td>0.6</td></tr><tr><td>Anti-Le<sup>a</sup></td><td>4</td><td>2.5</td></tr><tr><td>Anti-Lu<sup>a</sup></td><td>1</td><td>0.6</td></tr><tr><td>Anti-M</td><td>4</td><td>2.5</td></tr><tr><td colspan="3">Auto- + alloantibodies</td></tr><tr><td>Auto- + alloanti-c</td><td>2</td><td>1.3</td></tr><tr><td>Auto- + alloanti-E</td><td>3</td><td>1.9</td></tr><tr><td>Auto- + alloanti-K</td><td>3</td><td>1.9</td></tr><tr><td>Auto- + alloanti-S</td><td>1</td><td>0.6</td></tr><tr><td>Not determined</td><td>12</td><td>7.6</td></tr><tr><td>Total</td><td>157</td><td>&#8776;100% </td></tr></table>
e0392898e7c9e9c53e2fdc24038a41773f86e9d55318c317483fbdeb99e13bdb.png
simple
<table><tr><td>Genotype</td><td>Strain</td><td>Accession number</td><td>Genotype</td><td>Strain</td><td>Accession number</td></tr><tr><td>GI_1</td><td>NV-USA93</td><td>M87661</td><td>GII_6</td><td>SU3-JPN </td><td>AB039776</td></tr><tr><td>GI_2</td><td>SOV-GBR93</td><td>L07418</td><td>GII_7</td><td>GN273-USA93</td><td>AF414409</td></tr><tr><td>GI_3</td><td>VA98115-USA98</td><td>AY038598</td><td>GII_8</td><td>SaU25-JPN </td><td>AB039780</td></tr><tr><td>GI_4</td><td>B493-GER93 </td><td>X76716</td><td>GII_9</td><td>VA97207-USA97</td><td>AY038599</td></tr><tr><td>GI_5</td><td>SzUG1-JPN </td><td>AF414406</td><td>GII_10</td><td>Erfurt-DEU00</td><td>AF427118</td></tr><tr><td>GI_6</td><td>BS5-GER </td><td>AF093797</td><td>GII_11</td><td>SW918-JPN97</td><td>AB074893</td></tr><tr><td>GI_7</td><td>Wnchest-GBR94</td><td>AJ277609</td><td>GII_12</td><td>Gifu-JPN96</td><td>AB045603</td></tr><tr><td>GI_8</td><td>Boxer-USA01</td><td>AF538679</td><td>GII_13</td><td>G5175B-AUS83</td><td>DQ379714</td></tr><tr><td>GII_1</td><td>Hawaii-USA94</td><td>U07611</td><td>GII_14</td><td>8533Maizuru-JPN08</td><td>GU017903</td></tr><tr><td>GII_2</td><td>SMV2-USA</td><td>AY134748</td><td>GII_15</td><td>Me7076-USA99 </td><td>AF542090</td></tr><tr><td>GII_3</td><td>SU201-JPN </td><td>AB039782</td><td>GII_16</td><td>Tiffin-USA99</td><td>AY502010</td></tr><tr><td>GII_4</td><td>Lordsdale-UK</td><td>X86557</td><td>GII_17</td><td>CSE1-USA02</td><td>AY502009</td></tr><tr><td>GII_5</td><td>MOH-HUN99</td><td>AF397156</td><td></td><td></td><td></td></tr></table>
96571da16e013dba98706c25f7499c3575136d33ec53716a39a275558c4c12cd.png
complex
<table><tr><td>Characteristic</td><td>Bipolar I(<i>n</i> = 1809)</td><td>Bipolar II(<i>n</i> = 922)</td><td>Total(<i>N</i> = 2731)</td></tr><tr><td colspan="4">Gender, <i>n</i> (%)</td></tr><tr><td> Male</td><td>752 (41.6)</td><td>340 (36.9)</td><td>1092 (40.0)</td></tr><tr><td> Female</td><td>1057 (58.4)</td><td>582 (63.1)</td><td>1639 (60.0)</td></tr><tr><td>Mean age (years), mean (SD)</td><td>39.6 (11.5)</td><td>38.8 (11.9)</td><td>39.3 (11.6)</td></tr><tr><td>Mean body weight (kg), mean (SD)</td><td>83.4 (21.4)</td><td>79.7 (19.7)</td><td>82.1 (20.9)</td></tr></table>
b273f72720870a9eb0f06491269b21fa671e00ba3d8418576c983ccdf969ce79.png
simple
<table><tr><td> </td><td>0&#8211;30 days post-implant</td><td>31&#8211;60 days post-implant</td><td>61&#8211;90 days post-implant</td></tr><tr><td>Pacemaker</td><td>35%</td><td>30%</td><td>67%</td></tr><tr><td>ICD</td><td>36%</td><td>42%</td><td>66%</td></tr><tr><td>CRT-D</td><td>34%</td><td>32%</td><td>77%</td></tr></table>
b0422b2ff0e87dbcecb96fcf18ff320ce2f3836079c9d1e8c84eb0f91bfa4a6e.png
complex
<table><tr><td colspan="3">Categorical variables</td><td colspan="3">Symptoms class of SCIN-total-score</td><td colspan="2">Univariate</td><td colspan="2">Multiple&#8224;</td></tr><tr><td colspan="2">GST genotype</td><td>Number (%)</td><td>No (0&#8211;5)</td><td>Moderate (6&#8211;9)</td><td>Severe (10&#8211;18)</td><td>P</td><td>OR (95% CI)</td><td>P</td><td>OR (95% CI)</td></tr><tr><td>P1</td><td>A/A</td><td>99 (41.6)</td><td>60 (60.6)</td><td>23 (23.2)</td><td>16 (16.2)</td><td>0.098</td><td>2.03 (0.88&#8211;4.67)</td><td>0.012</td><td>3.84 (1.34&#8211;10.75)</td></tr><tr><td></td><td>A/G</td><td>102 (42.9)</td><td>53 (52.0)</td><td>29 (28.4)</td><td>20 (19.6)</td><td>0.014</td><td>2.83 (1.24&#8211;6.46)</td><td>0.003</td><td>4.95 (1.70&#8211;14.45)</td></tr><tr><td></td><td>G/G</td><td>37 (15.5)</td><td>27 (73.0)</td><td>10 (27.0)</td><td>0 (0)</td><td colspan="4">Reference for <i>GSTP1-AA </i>and <i>-AG</i></td></tr><tr><td>T1</td><td>+</td><td>201 (84.5)</td><td>118 (58.7)</td><td>51 (25.4)</td><td>32 (15.9)</td><td>0.770</td><td>1.11 (0.55&#8211;2.22)</td><td>0.714</td><td>1.17 (0.50&#8211;2.73)</td></tr><tr><td></td><td>- (ref.)</td><td>37 (15.5)</td><td>22 (59.5)</td><td>11 (29.7)</td><td>4 (10.8)</td><td></td><td></td><td></td><td></td></tr><tr><td>M1</td><td>+</td><td>134 (56.3)</td><td>79 (59.0)</td><td>35 (26.1)</td><td>20 (14.9)</td><td>0.947</td><td>0.98 (0.59&#8211;1.63)</td><td>0.166</td><td>1.56 (0.83&#8211;2.94)</td></tr><tr><td></td><td>- (ref.)</td><td>104 (43.7)</td><td>61 (58.7)</td><td>27 (26.0)</td><td>16 (15.4)</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Continuous variables</td><td>TCSs N (%)</td><td>Median</td><td>Minimum</td><td>Maximum</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Age at survey (OR for 10 years)</td><td>238 (100%)</td><td>42.3</td><td>22.7</td><td>73.4</td><td>0.008</td><td>1.40 (1.09&#8211;1.80)</td><td>0.002</td><td>1.70 (1.22&#8211;2.36)</td></tr><tr><td>OR*</td><td>Cisplatin</td><td>238 (100%)</td><td>397</td><td>81</td><td>1571</td><td>&lt;0.001</td><td>1.35 (1.11&#8211;1.49)</td><td>0.014</td><td>1.35 (1.06&#8211;1.71)</td></tr><tr><td></td><td>Bleomycin</td><td>226 (95.0%)</td><td>142</td><td>0</td><td>212</td><td>0.040</td><td>1.65 (1.00&#8211;2.72)</td><td><i>0.078</i></td><td><i>1.43 (0.93&#8211;2.13)</i></td></tr><tr><td></td><td>Vinblastine</td><td>133 (55.9%)</td><td>9.9</td><td>0</td><td>51</td><td>0.535</td><td>1.49 (0.41&#8211;6.05)</td><td>0.319</td><td>0.23 (0.01&#8211;4.14)</td></tr><tr><td></td><td>Etoposide</td><td>92 (38.7%)</td><td>727</td><td>0</td><td>4934</td><td>0.092</td><td>1.00 (1.00&#8211;1.00)</td><td>0.918</td><td>1.00 (0.90&#8211;1.11)</td></tr></table>
8f7c0fcd53d9c85fe17f95cf121fdfc5b951951355c2c609309018083bbbf990.png
complex
<table><tr><td></td><td colspan="4">Unmatched cohorts</td><td colspan="3">Propensity-score matched cohorts</td></tr><tr><td>Complications</td><td>Human regular insulin <i>n</i> (%) </td><td>Rapid-acting Insulin Analogues <i>n</i> (%) </td><td>Adjusted HR<sup>a</sup> (95% CI)</td><td colspan="2">Human regular insulin <i>n</i> (%) </td><td>Rapid-acting Insulin Analogues <i>n</i> (%) </td><td>HR (95% CI)</td></tr><tr><td>Any complication</td><td>286 (31.3)</td><td>235 (17.1)</td><td>0.56 (0.45-0.69)</td><td colspan="2">165 (29.1)</td><td>132 (23.3)</td><td>0.73 (0.58-0.92)</td></tr><tr><td>Macrovascular </td><td>203 (22.2)</td><td>147 (10.7)</td><td>0.56 (0.43-0.72)</td><td colspan="2">110 (19.4)</td><td>87 (15.4)</td><td>0.73 (0.55-0.95)</td></tr><tr><td>Cardiovascular disease</td><td>107 (11.7)</td><td>95 (6.9)</td><td>0.62 (0.44-0.86)</td><td colspan="2">63 (11.1)</td><td>53 (9.4)</td><td>0.77 (0.54-1.10)</td></tr><tr><td>Peripheral vascular disease </td><td>21 (2.3)</td><td>14 (1.0)</td><td>0.32 (0.14-0.75)</td><td colspan="2">14 (2.5)</td><td>8 (1.4)</td><td>0.53 (0.22-1.27)</td></tr><tr><td>Cerebrovascular disease </td><td>75 (8.2)</td><td>38 (2.8)</td><td>0.55 (0.35-0.88)</td><td colspan="2">33 (5.8)</td><td>26 (4.6)</td><td>0.73 (0.44-1.20)</td></tr><tr><td>Microvascular </td><td>43 (4.7)</td><td>53 (3.9)</td><td>0.73 (0.45-1.20)</td><td colspan="2">27 (4.8)</td><td>26 (4.6)</td><td>0.89 (0.54-1.48)</td></tr><tr><td>Metabolic </td><td>52 (5.7)</td><td>37 (2.7)</td><td>0.36 (0.21-0.59)</td><td colspan="2">35 (6.2)</td><td>21 (3.7)</td><td>0.55 (0.32-0.94)</td></tr><tr><td>Hyperglycemia</td><td>34 (3.7)</td><td>21 (1.5)</td><td>0.36 (0.21-0.59)</td><td colspan="2">21 (3.7)</td><td>11 (1.9)</td><td>0.48 (0.23-0.99)</td></tr><tr><td>Hypoglycemia</td><td>19 (2.1)</td><td>16 (1.2)</td><td>0.51 (0.23-1.12)</td><td colspan="2">14 (2.5)</td><td>12 (2.1)</td><td>0.62 (0.29-1.34)</td></tr></table>
242cf30cfa41e9991f75c5dae55bf35e2f5989ae4e03bd4fc24efa147be68f29.png
complex
<table><tr><td> </td><td colspan="2">Males</td><td colspan="2">Females</td></tr><tr><td> </td><td>AOR</td><td>95% CI</td><td>AOR</td><td>95% CI</td></tr><tr><td>HIV Prevalence</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&#8804; 0.37%</td><td>1.0</td><td>-</td><td>1.0</td><td>-</td></tr><tr><td>0.38-0.73%</td><td>1.1</td><td>0.67, 1.7</td><td>1.5</td><td>0.84, 2.7</td></tr><tr><td>0.74%-1.3%</td><td>1.3</td><td>0.81, 2.2</td><td>1.7</td><td>0.90, 3.1</td></tr><tr><td>1.3-1.65%</td><td>1.2</td><td>0.73, 2.0</td><td>1.1</td><td>0.56, 2.1</td></tr><tr><td>&gt; 1.65%</td><td>1.1</td><td>0.71, 1.9</td><td>2.3</td><td>1.2, 2.7</td></tr><tr><td>MSM Proportion</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&#8804; 5.7%</td><td>1.0</td><td>-</td><td>1.0</td><td>-</td></tr><tr><td>5.8-7.0%</td><td>1.2</td><td>0.72, 1.9</td><td>1.9</td><td>1.0, 3.5</td></tr><tr><td>7.1-8.0%</td><td>1.3</td><td>0.86, 1.9</td><td>1.4</td><td>0.84, 2.5</td></tr><tr><td>8.1-9.8%</td><td>1.7</td><td>1.1, 2.7</td><td>2.0</td><td>1.1, 3.6</td></tr><tr><td>&gt; 9.8%</td><td>1.2</td><td>0.76, 1.8</td><td>1.5</td><td>0.82, 2.7</td></tr><tr><td>Income per year ($)</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&#8804; 26,000</td><td>0.94</td><td>0.64, 1.4</td><td>0.95</td><td>0.55, 1.6</td></tr><tr><td>26,001-35,000</td><td>0.76</td><td>0.49, 1.2</td><td>0.58</td><td>0.32, 1.1</td></tr><tr><td>35,000-41,000</td><td>1.3</td><td>0.85, 1.9</td><td>0.89</td><td>0.49, 1.6</td></tr><tr><td>41,000-48,000</td><td>0.69</td><td>0.45, 1.0</td><td>0.72</td><td>0.41, 1.3</td></tr><tr><td>&gt; 48,000</td><td>1.0</td><td>-</td><td>1.0</td><td>-</td></tr><tr><td>ED Usage Rate*</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>&#8804; 24,000</td><td>1.0</td><td>-</td><td>1.0</td><td>-</td></tr><tr><td>24,001-32,600</td><td>0.63</td><td>0.40, 1.0</td><td>0.98</td><td>0.51, 1.9</td></tr><tr><td>32,601-44,200</td><td>0.92</td><td>0.62, 1.4</td><td>1.2</td><td>0.69, 2.2</td></tr><tr><td>44,201-56,000</td><td>1.0</td><td>0.70, 1.6</td><td>1.2</td><td>0.64, 2.2</td></tr><tr><td>&gt; 56,000</td><td>0.83</td><td>0.55, 1.3</td><td>1.4</td><td>0.76, 2.6</td></tr></table>
d21eee8130a8fec31d2d4339c69fac3f55473a40217e4f3325d1f1e081d25ec7.png
simple
<table><tr><td>Species</td><td>Number detected</td><td>(high; medium; low; no visible mould)</td></tr><tr><td><i>Epicoccum nigrum</i></td><td>15</td><td>(7,2,4,2)</td></tr><tr><td><i>Cladosporium cladosporioides</i></td><td>7</td><td>(3,3,1,0)</td></tr><tr><td><i>Aureobasidium pullulan</i></td><td>4</td><td>(1,1,2,0)</td></tr><tr><td><i>Cryptococcus flavescens</i></td><td>3</td><td>(1,2,0,0)</td></tr><tr><td><i>Alternaria alternata</i></td><td>2</td><td>(1,1,0,0)</td></tr><tr><td><i>Alternaria tenuissima</i></td><td>1</td><td>(0,0,1,0)</td></tr><tr><td><i>Aspergillus westerdijkiae</i></td><td>1</td><td>(0,0,1,0)</td></tr><tr><td><i>Candida parapsilosis</i></td><td>1</td><td>(0,1,0,0)</td></tr><tr><td><i>Cladosporium silenes</i></td><td>1</td><td>(0,0,0,1)</td></tr><tr><td><i>Cladosporium tenuissimum</i></td><td>1</td><td>(0,1,0,0)</td></tr><tr><td><i>Cladosporium uredinicola</i></td><td>1</td><td>(1,0,0,0)</td></tr><tr><td><i>Cochliobolus lunatus</i></td><td>1</td><td>(0,1,0,0)</td></tr><tr><td><i>Curvularia brachyspora</i></td><td>1</td><td>(0,1,0,0)</td></tr><tr><td><i>Curvularia trifolii</i></td><td>1</td><td>(0,1,0,0)</td></tr><tr><td><i>Leptosphaerulina australis</i></td><td>1</td><td>(0,1,0,0)</td></tr><tr><td><i>Paraphaeosphaeria sp</i></td><td>1</td><td>(1,0,0,0)</td></tr><tr><td><i>Penicillium fellutanum</i></td><td>1</td><td>(0,0,1,0)</td></tr><tr><td><i>Penicillium oxalicum</i></td><td>1</td><td>(0,1,0,0)</td></tr><tr><td><i>Penicillium polonicum</i></td><td>1</td><td>(0,0,0,1)</td></tr><tr><td><i>Penicillium spinulosum</i></td><td>1</td><td>(0,0,1,0)</td></tr><tr><td><i>Phoma herbarum</i></td><td>1</td><td>(0,0,1,0)</td></tr><tr><td><i>Rhodotorula slooffiae</i></td><td>1</td><td>(0,1,0,0)</td></tr><tr><td>Total</td><td>48</td><td> </td></tr></table>
797f0effba259b4e68a1f023b5e4f0b86ef6ec09e2688f1d0b603a17f1c06e7f.png
simple
<table><tr><td>Complications</td><td>Survivors (n = 46)</td><td>Non-survivors (n = 29)</td><td>P value<sup>a</sup></td></tr><tr><td>ARDS, n (%)</td><td>17 (37.6)</td><td>25 (86.2)</td><td>&lt;.001</td></tr><tr><td>Pneumonia, n (%)</td><td>41 (89.1)</td><td>27 (93.1)</td><td>.866</td></tr><tr><td>Arrhythmia, n (%)</td><td>9 (19.6)</td><td>8 (27.6)</td><td>.419</td></tr><tr><td>Alimentary tract hemorrhage, n (%)</td><td>17 (37)</td><td>17 (58.6)</td><td>.066</td></tr><tr><td>Cardiac failure, n (%)</td><td>3 (6.5)</td><td>11(39.3)</td><td>&lt;.001</td></tr><tr><td>Hyperglycemia, n (%)</td><td>36 (78.3)</td><td>25 (86.2)</td><td>.390</td></tr><tr><td>Encephalopathy, n (%)</td><td>11 (23.9)</td><td>28 (96.6)</td><td>&lt;.001</td></tr><tr><td>Concurrent bacteremia, n (%)</td><td>13 (28.3)</td><td>8 (27.6)</td><td>.949</td></tr><tr><td>Secondary hypertension, n (%)</td><td>26 (56.5)</td><td>10 (34.5)</td><td>.063</td></tr><tr><td>ARF, n (%)</td><td>42 (91.3)</td><td>20 (69.0)</td><td>.013</td></tr></table>
4365e1113c9bc0cf76d2599cb1705943e611441cb404884c11323694de9b80d7.png
complex
<table><tr><td colspan="2">ROSA item</td><td>Symptom domain</td><td>Factor</td><td>Loading</td></tr><tr><td>1</td><td>The patient is able to remember events from a long time ago.</td><td>Cognition</td><td>Factor 1</td><td>0.6857</td></tr><tr><td>2</td><td>The patient is able to remember events of the recent past.</td><td>Cognition</td><td></td><td>0.7448</td></tr><tr><td>3</td><td>The patient is able to plan and carry out complex procedures.</td><td>Cognition</td><td></td><td>0.8526</td></tr><tr><td>4</td><td>The patient is able to make himself understood.</td><td>Communication</td><td></td><td>0.7138</td></tr><tr><td>5</td><td>The patient is able to communicate.</td><td>Communication</td><td></td><td>0.7966</td></tr><tr><td>6</td><td>The patient shows social competence.</td><td>Communication</td><td></td><td>0.7289</td></tr><tr><td>12</td><td>The patient is competent at everyday tasks.</td><td>Function/ADL</td><td></td><td>0.7791</td></tr><tr><td>13</td><td>The patient is attentive, shows interest in his surroundings.</td><td>Function/ADL</td><td></td><td>0.7284</td></tr><tr><td>14</td><td>The patient is independent.</td><td>Function/ADL</td><td></td><td>0.7849</td></tr><tr><td>15</td><td>The patient's quality of life is (very good/very poor).</td><td>Quality of life</td><td></td><td>0.4509</td></tr><tr><td>16</td><td>The burden for the caregiver is (very small/very large).</td><td>Caregiver burden</td><td></td><td>0.6183</td></tr><tr><td>7</td><td>The patient behaves aggressively.</td><td>Behavior</td><td>Factor 2</td><td>0.7309</td></tr><tr><td>8</td><td>The patient is restless.</td><td>Behavior</td><td></td><td>0.6248</td></tr><tr><td>9</td><td>The patient shows behavioral changes due to delusions.</td><td>Behavior</td><td></td><td>0.7397</td></tr><tr><td>10</td><td>The patient is insecure.</td><td>Behavior</td><td></td><td>0.5014</td></tr><tr><td>11</td><td>The patient's behavior is cooperative.</td><td>Behavior</td><td></td><td>0.6243</td></tr></table>
3825c1ca913079c36b99321c86fc65aa6b50dc7fd38a4644ea62c4a553cdee9b.png
complex
<table><tr><td></td><td>Hill and Upchurch7</td><td>Alkema <i>et al</i>2</td></tr><tr><td>Type</td><td>Prescriptive</td><td>Descriptive</td></tr><tr><td>Data</td><td>Historical series from four Northwestern European countries (England and Wales, France, the Netherlands and Sweden) and New Zealand, between 1820 and 1964</td><td>All available data from vital registration systems, sample registration and surveillance systems, surveys and censuses from 195 countries since 1950.</td></tr><tr><td>Age ranges</td><td colspan="2">Infant (&lt;1 year), child (1&#8211;4 years) and under 5 (&lt;5 years)</td></tr><tr><td></td><td rowspan="2">Intended to reflect sex differentials in childhood mortality in the absence of substantial discrimination, but at relatively high levels of child mortality. Described by the authors as a mortality &#8216;standard&#8217;.</td><td rowspan="2">Intended to reflect actual sex ratios in mortality, regardless of the presence of gender bias. Country-specific sex ratios are presented; these results are based on the product of the expected sex ratio and a country-specific multiplier, which represents the relative advantage or disadvantage of girls to boys compared with other countries with similar total mortality rates.</td></tr><tr><td>Original estimates</td></tr><tr><td>Assessment of gender bias</td><td>Female advantage index (difference between the observed and expected female/male mortality ratios) for any given level of male mortality</td><td>Countries with outlying sex ratios. Excess female mortality expressed as the difference between the expected and estimated female mortality rates</td></tr></table>
04e2fc55ef09fa6496ca2868f1c0e157a7225a1872560c46ade7c1b1bd7f484f.png
complex
<table><tr><td>Domain name and number</td><td>ROC set No.</td><td>ROC variables</td><td>No. Obs</td><td>AUC</td><td>SENS</td><td>SPEC</td><td>PPV</td><td>NPV</td><td>% Risk of rejecting Ho</td><td>ROC <i>P</i> value</td><td>Odds ratio<sup>+</sup></td><td>Odds ratio <i>P</i> value</td><td>Accuracy</td></tr><tr><td rowspan="3">1. Visual</td><td>1</td><td>Low visual span</td><td>126</td><td>0.862</td><td>0.831</td><td>0.821</td><td>0.021</td><td>0.999</td><td>0.01</td><td>&lt;0.0001</td><td>22.46</td><td>&lt;0.0001</td><td>0.8254</td></tr><tr><td>2</td><td>High visual speed of processing discrepancy (% of age)</td><td>122</td><td>0.875</td><td>0.909</td><td>0.731</td><td>0.015</td><td>0.999</td><td>0.01</td><td>&lt;0.0001</td><td>27.22</td><td>&lt;0.0001</td><td>0.8115</td></tr><tr><td>3</td><td>Poor distance vision on right</td><td>128</td><td>0.597</td><td>0.475</td><td>0.851</td><td>0.014</td><td>0.997</td><td>0.01</td><td>&lt;0.0001</td><td>5.17</td><td>0.0001</td><td>0.6719</td></tr><tr><td rowspan="3">2. Auditory</td><td>4</td><td>Low reverse digit span</td><td>127</td><td>0.810</td><td>0.900</td><td>0.552</td><td>0.009</td><td>0.999</td><td>0.02</td><td>0.000</td><td>11.1</td><td>&lt;0.0001</td><td>0.8707</td></tr><tr><td>5</td><td>High competing words discrepancy (% of pass score) (represents dichotic listening disorder)</td><td>124</td><td>0.799</td><td>0.759</td><td>0.773</td><td>0.015</td><td>0.999</td><td>0.01</td><td>&lt;0.0001</td><td>10.69</td><td>&lt;0.0001</td><td>0.8362</td></tr><tr><td>6</td><td>High auditory speed of processing discrepancy (% of age)</td><td>121</td><td>0.874</td><td>0.745</td><td>0.879</td><td>0.027</td><td>0.999</td><td>0.01</td><td>&lt;0.0001</td><td>21.23</td><td>&lt;0.0001</td><td>0.6810</td></tr><tr><td rowspan="3">3. Catecholamine</td><td>7</td><td>High dopamine</td><td>133</td><td>0.702</td><td>0.379</td><td>0.940</td><td>0.028</td><td>0.997</td><td>0.01</td><td>&lt;0.0001</td><td>9.60</td><td>&lt;0.0001</td><td>0.6617</td></tr><tr><td>8</td><td>High noradrenaline</td><td>133</td><td>0.851</td><td>0.742</td><td>0.881</td><td>0.027</td><td>0.999</td><td>0.01</td><td>&lt;0.0001</td><td>21.25</td><td>&lt;0.0001</td><td>0.8120</td></tr><tr><td>9</td><td>High adrenaline</td><td>133</td><td>0.844</td><td>0.758</td><td>0.821</td><td>0.019</td><td>0.999</td><td>0.01</td><td>&lt;0.0001</td><td>14.32</td><td>&lt;0.0001</td><td>0.7895</td></tr><tr><td>4. Oxidative stress</td><td>10</td><td>High (HPL/creatinine)<sup>a</sup> (oxidative stress domain)</td><td>133</td><td>0.696</td><td>0.697</td><td>0.642</td><td>0.009</td><td>0.998</td><td>0.01</td><td>&lt;0.0001</td><td>4.12</td><td>&lt;0.0001</td><td>0.6692</td></tr><tr><td rowspan="5">5. Biochemistry&#8211;nutrition</td><td>11</td><td>High free copper to zinc ratio</td><td>133</td><td>0.611</td><td>0.470</td><td>0.746</td><td>0.008</td><td>0.997</td><td>2.19</td><td>0.022</td><td>2.60</td><td>0.0104</td><td>0.6090</td></tr><tr><td>12</td><td>Low B6 activation</td><td>129</td><td>0.638</td><td>0.800</td><td>0.484</td><td>0.008</td><td>0.997</td><td>0.17</td><td>0.002</td><td>3.75</td><td>0.0009</td><td>0.6434</td></tr><tr><td>13</td><td>Low red cell folate</td><td>133</td><td>0.654</td><td>0.591</td><td>0.716</td><td>0.009</td><td>0.997</td><td>0.10</td><td>0.001</td><td>3.64</td><td>0.0005</td><td>0.6541</td></tr><tr><td>14</td><td>High serum B12 (80% CI)</td><td>134</td><td>0.565</td><td>0.373</td><td>0.761</td><td>0.007</td><td>0.996</td><td>18.56</td><td>0.186</td><td>1.89</td><td>0.0933</td><td>0.5672</td></tr><tr><td>15</td><td>Low vitamin D</td><td>132</td><td>0.651</td><td>0.462</td><td>0.791</td><td>0.010</td><td>0.997</td><td>0.12</td><td>0.001</td><td>3.24</td><td>0.0026</td><td>0.6288</td></tr></table>
bb57ff60a2c624b34fc1cbcd8535a43a16bbd3f6f0a647380e811cc4f48c55a2.png
simple
<table><tr><td>Chemokine</td><td>Forward primer</td><td>Reverse primer</td><td>Product size (bp)</td></tr><tr><td>CCL-chr25s</td><td>5'-TTCTGCTGTTTTTGGTGTTCA</td><td>5'-GCTTTATCCAGTCCTCATCTGG</td><td>216</td></tr><tr><td>CCL-chr24a</td><td>5'-TACTTCTCAGCTTCCTTGTGGAGA</td><td>5'-CTCATCGTCTTCGTCTTCATTGTT</td><td>250</td></tr><tr><td>CXL-chr24a</td><td>5'-AGGTTGGAGCAGTACCGACAA</td><td>5'-CCTCCCCTCTACACGTTACCC</td><td>245</td></tr><tr><td>CCL-chr24c</td><td>5'-ATGCGTCTGTCCTCAGCTTT</td><td>5'-GCTGTCGGATCTATGCAGTG</td><td>284</td></tr><tr><td>CCL-chr24m</td><td>5'-AGGAGTTTGGCTGTTGCACT</td><td>5'-CCTCCTCACCCACAGTTGTC</td><td>219</td></tr><tr><td>CCL-chr20d</td><td>5'-CAGACAAGTGCTGCTTTTCG</td><td>5'-GAGCTGGCCTCTGTGTCTTT</td><td>209</td></tr><tr><td>CCL-chr20g</td><td>5'-CGCTTTCTGCTCAGTTGTTG</td><td>5'-TCAGTCTCCGAACCCATTTC</td><td>215</td></tr><tr><td>scyba<i>a</i></td><td>5'-TGCAGATGCACAAGAAAAGG</td><td>5'-GGCTTCAAACGTCCTGTGTT</td><td>225</td></tr><tr><td>cxcl12a<i>a</i></td><td>5'-TTCATGCACCGATTTCCAAC</td><td>5'-TGTTGATGGCGTTCTTCAGG</td><td>222</td></tr><tr><td>CXCL-chr13a</td><td>5'-CAACATGTCCCAAAGACCTG</td><td>5'-TTACCTGTTCCAACATTTCATTAGA</td><td>201</td></tr><tr><td>CXCL-chr13c</td><td>5'-ACTGCCCATCCAGCAGTTAC</td><td>5'-TCCTGCCTTCGATGATCTTT</td><td>200</td></tr><tr><td>CXCL-chr13d</td><td>5'-TTGTTTTTGGAGTCAGCATCA</td><td>5'-AGTGTGTTCTGGGGTTCAGG</td><td>222</td></tr><tr><td>CCL-chr11a</td><td>5'-CCAGCATCGCACAAGGTTAC</td><td>5'-GCCTGGACCCAGTCACTTCT</td><td>208</td></tr><tr><td>CCL-chr11b</td><td>5'-ATGCAGCGAGATGTTCAGTG</td><td>5'-GGAATTCACAACAGCGACCT</td><td>282</td></tr><tr><td>CCL-chr10a</td><td>5'-CGATGATGCAGTGGATTGTT</td><td>5'-TTTCCTGGGTCGTTTTTGTG</td><td>235</td></tr><tr><td>CCL-chr10b</td><td>5'-TACTGTGCATCGCCTTCAGC</td><td>5'-TAGACGAGCCATTCGCTTCA</td><td>233</td></tr><tr><td>ccl1<i>a</i></td><td>5'-GGCACGAGATGGAGTTCAGA</td><td>5'-GCCGTCTGTATCCGTGATTT</td><td>329</td></tr><tr><td>CCL-chr5a</td><td>5'-ACGGTCAGCCCAAGAGTCAT</td><td>5'-GAGCATGACAGCGTCTCTCG</td><td>229</td></tr><tr><td>CCL-chr5b</td><td>5-CCATAACTCTCCTGCTCATCG</td><td>5'-GCGCAGAGTTTCTTGTCCTT</td><td>202</td></tr><tr><td>CXCL-chr5c</td><td>5'-AAGTGCGTGCCTGATAAACC</td><td>5'-CACATCAACTGCCTGAATGG</td><td>229</td></tr><tr><td>CXCL-chr5d</td><td>5'-TGTTACTGCTCTGCTTCTTGTCA</td><td>5'-CATCGTTTTCCAGCTCCATT</td><td>204</td></tr><tr><td>CXCL-chr1c</td><td>5'-TACGTCCAGCAGGGAGAAGT</td><td>5'-CCCTGCTGTTTTTGTGGATT</td><td>218</td></tr><tr><td>CCL-chrUi</td><td>5'-GACTTCTGGCCGTCACATTC</td><td>5'-AGCTGAGGGTCCACACAGAG</td><td>202</td></tr><tr><td>&#946;-actin</td><td>5'-TGTTCGAGACCTTCAACACC</td><td>5'-TGAAGGTGGTCTCGTGGATA</td><td>471</td></tr></table>
1a4f944a7f32d980972b2b639b4015c0eabc555da90f578f207c0d782cc27b0c.png
complex
<table><tr><td>Gender</td><td colspan="2">Male</td></tr><tr><td>Age</td><td colspan="2">10 y</td></tr><tr><td>Diagnosis</td><td colspan="2">Oppositional defiant disorder</td></tr><tr><td>Intellligence quotient (IQ)</td><td colspan="2">59</td></tr><tr><td>NCBRF total score</td><td></td><td></td></tr><tr><td> Baseline</td><td colspan="2">33</td></tr><tr><td> Endpoint</td><td colspan="2">31</td></tr><tr><td>Time point</td><td>Risperidone dose (mg/day)</td><td>Dyskinesia score*</td></tr><tr><td> Baseline</td><td>0.000</td><td>3</td></tr><tr><td> Week 1</td><td>0.343</td><td>3</td></tr><tr><td> Week 2</td><td>1.200</td><td>3</td></tr><tr><td> Week 3</td><td>1.814</td><td>3</td></tr><tr><td> Week 4</td><td>1.900</td><td>3</td></tr><tr><td> Week 8</td><td>1.784</td><td>---</td></tr><tr><td> Week 12</td><td>1.300</td><td>4</td></tr><tr><td> Week 16</td><td>1.300</td><td>7</td></tr><tr><td> Week 20</td><td>1.300</td><td>7</td></tr><tr><td> Week 24</td><td>1.300</td><td>1</td></tr><tr><td> Week 36</td><td>1.300</td><td>2</td></tr><tr><td> Week 48</td><td>1.300</td><td>0</td></tr></table>
ad00f63b01ab13e483569ceb153c455474ad5006f486b5ebe9f3ff619a9ac7d4.png
simple
<table><tr><td></td><td>Screening</td><td>Pretreatment</td><td>Discharge</td><td>End of Intervention</td><td>Follow-up</td></tr><tr><td>Study visits</td><td></td><td>T0</td><td>T1</td><td>T2</td><td>T3</td></tr><tr><td>Written informed consent</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Screening questions</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>BDI-II</td><td>X</td><td></td><td>X</td><td>X</td><td>X</td></tr><tr><td>GAD-7</td><td></td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>PHQ-9</td><td></td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>RSE</td><td></td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>EUROHIS-QOL 8</td><td></td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>DAS</td><td></td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>CTQ</td><td></td><td>X</td><td></td><td></td><td></td></tr><tr><td>WAI</td><td></td><td>X</td><td>X</td><td></td><td>X</td></tr><tr><td>OPD-SQ</td><td></td><td>X</td><td></td><td></td><td></td></tr><tr><td>HAQ</td><td></td><td></td><td>X</td><td></td><td></td></tr><tr><td>Satisfaction with intervention</td><td></td><td></td><td>X</td><td>X</td><td></td></tr><tr><td>Utilization of other treatment</td><td></td><td></td><td></td><td></td><td>X</td></tr><tr><td>BADO</td><td></td><td>X</td><td>X</td><td></td><td></td></tr><tr><td>Willingness to pay</td><td></td><td></td><td></td><td>X</td><td></td></tr><tr><td>Adverse events</td><td></td><td>continuously</td><td>X</td><td>X</td><td></td></tr></table>
25dde062e7f93af4555fda3db5c415a90fcfacc51556fa70f4a0b552f1eb354e.png
complex
<table><tr><td rowspan="2">Goal</td><td rowspan="2">I have set this goal (<i>N</i>)</td><td rowspan="2">Since joining K-DPP, I have made lifestyle changes to achieve this goal (%)</td><td colspan="3">I will continue to make these changes after the intervention</td></tr><tr><td>Very likely (%)</td><td>Likely (%)</td><td>Not sure (%)</td></tr><tr><td>Improving diet</td><td>346</td><td>99</td><td>83</td><td>15</td><td>2</td></tr><tr><td>Increasing physical activity</td><td>306</td><td>96</td><td>67</td><td>32</td><td>1</td></tr><tr><td>Reducing smoking/tobacco</td><td>51</td><td>76</td><td>82</td><td>18</td><td>&#8211;</td></tr><tr><td>Reducing alcohol consumption</td><td>62</td><td>98</td><td>56</td><td>34</td><td>10</td></tr></table>
3feac42582fc27ac74384718b9fbeafd304bf75628d19ee29cec85efa9e3bf13.png
simple
<table><tr><td>Isoform</td><td>Substrate</td><td>Metabolite</td><td>Ranges of substrate concentrations in the incubations, &#956;M</td><td>Fluorescence detection excitation/emission</td></tr><tr><td>CYP1A</td><td>ER</td><td>resorufin</td><td>0.1&#8211;12.0</td><td>560/586 nm</td></tr><tr><td>CYP2A</td><td>coumarin</td><td>hydroxycoumarin</td><td>2.5&#8211;300.0</td><td>338/458 nm</td></tr><tr><td>CYP3A</td><td>BFC</td><td>HFC</td><td>0.4&#8211;120.0</td><td>410/538 nm</td></tr></table>
3fc81942f717d9bb8dc56175eef9044b2651a3669868587e5eb6785c6e7a376c.png
complex
<table><tr><td>SNPs</td><td>No. of every SNP type</td><td>Caused by</td><td>Total No. of transition and transversion</td></tr><tr><td>A/G</td><td>28769</td><td rowspan="2">Transition</td><td rowspan="2">53208</td></tr><tr><td>C/T</td><td>24439</td></tr><tr><td>A/C</td><td>6832</td><td rowspan="4">Transversion</td><td rowspan="4">30667</td></tr><tr><td>G/T</td><td>12016</td></tr><tr><td>A/T</td><td>4315</td></tr><tr><td>G/C</td><td>7504</td></tr></table>
3643a862c28b44139ae096ec26c766f3ef21ec85ee067d78f30dc287ea94ee78.png
simple
<table><tr><td>Term</td><td>Definition</td></tr><tr><td>SP-trEMBL</td><td>Sequence dataset containing 2,241,227 sequences from the Swiss-Prot (version 48.1) and TrEBML (version 31.1) sequence databases.</td></tr><tr><td>Integr8_263</td><td>Sequence dataset containing 913,094 sequences from 263 completed genomes listed in the Integr8 genome database.</td></tr><tr><td>Pfam_struc</td><td>Pfam-A family containing a PDB structure that has not yet been classified into the CATH domain database.</td></tr><tr><td>NewFam</td><td>Protein families generated in the Gene3D</td></tr></table>
b8163d45e8a1a6872fc8d05a543655ed4ca02a8c3007bd50787b5ceca8bc4c99.png
simple
<table><tr><td></td><td>EDA group (n = 68)</td><td>Opioid group (n = 98)</td><td>p-value</td></tr><tr><td>Age (years)</td><td>59.3 &#177; 16.0</td><td>59.9 &#177; 15.3</td><td>n.s.</td></tr><tr><td>Male gender (%)</td><td>58.8</td><td>66.3</td><td>n.s.</td></tr><tr><td>Hospital stay (days)</td><td>9.8 &#177; 5.7</td><td>11.1 &#177; 9.4</td><td>n.s.</td></tr><tr><td>Pre-existing pain therapy (%)</td><td>8.8</td><td>9.2</td><td>n.s.</td></tr><tr><td>Dismission with oral opioid (%)</td><td>73.5</td><td>76.5</td><td>n.s.</td></tr><tr><td>Opiod dose after dismission (mg)</td><td>27.7 &#177; 15.2</td><td>28.3 &#177; 16.4</td><td>n.s.</td></tr><tr><td>Time to first dejection (days)</td><td>3.5 &#177; 1.8</td><td>3.9 &#177; 2.2</td><td>n.s.</td></tr><tr><td>EDA duration (days)</td><td>4.5 &#177; 2.0</td><td>-</td><td></td></tr></table>
000221630ba33f9118f2671a715d6962e08d6b76a5a0c77a9fe26c291df763b0.png
complex
<table><tr><td></td><td colspan="2">PD-L1 Expression</td><td><i>*P</i> value</td></tr><tr><td></td><td>+</td><td>-</td><td></td></tr><tr><td>E-Cadherin</td><td></td><td></td><td></td></tr><tr><td>Down-regulated (&#8804;70 %)</td><td>9 (47)<sup>a</sup></td><td>10 (53)</td><td>0.039</td></tr><tr><td>Positive (&gt; 70 %)</td><td>10 (21)</td><td>38 (79)</td><td></td></tr><tr><td>Vimentin</td><td></td><td></td><td></td></tr><tr><td>Up-regulated (&gt; 5 %)</td><td>10 (53)</td><td>9 (47)</td><td>0.014</td></tr><tr><td>Negative (&lt;5 %)</td><td>9 (19)</td><td>39 (81)</td><td></td></tr><tr><td>E-Cadherin-down/Vimentin-up</td><td></td><td></td><td></td></tr><tr><td>Present</td><td>6 (75)</td><td>2(25)</td><td>0.005</td></tr><tr><td>Absent</td><td>13 (22)</td><td>46 (78)</td><td></td></tr></table>
aaee931a2962f3d966b27880c7684593d5a03d18218a71a870277745b3cff977.png
complex
<table><tr><td>Reference</td><td colspan="2">Numbers studied</td><td>Type of controls</td><td>Susceptibility</td><td>Severity</td><td>Ethnicity</td></tr><tr><td></td><td>Cancer</td><td>Controls</td><td></td><td></td><td></td><td></td></tr><tr><td>Hefler LA et al, 2005 [58]</td><td>269</td><td>227</td><td>Women visiting outpatient dept for various reasons</td><td>No association</td><td>No association</td><td>Caucasian</td></tr><tr><td>Our study</td><td>691</td><td>420</td><td>Women with normal mammograms from screening population</td><td>No association</td><td>No association</td><td>British Caucasian</td></tr></table>
ab8fda155873ef049ed4f29a6a4707c13f1b03dbd083de3fba9590d487a23146.png
complex
<table><tr><td></td><td colspan="4">Region of interest (ROI)</td></tr><tr><td>Period (months)</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td colspan="5">Monoblock</td></tr><tr><td> 0&#8211;12</td><td>&#8211;0.16 (&#8211;0.22 to &#8211;0.10)</td><td>&#8211;0.16 (&#8211;0.24 to &#8211;0.08)</td><td>&#8211;0.09 (&#8211;0.15 to &#8211;0.03)</td><td>&#8211;0.07 (&#8211;0.11 to &#8211;0.04)</td></tr><tr><td> 12&#8211;24</td><td>&#8211;0.04 (&#8211;0.11 to 0.07)</td><td>&#8211;0.10 (&#8211;0.21 to 0.02)</td><td>0.00(&#8211;0.05 to 0.06)</td><td>0.00 (&#8211;0.03 to 0.03)</td></tr><tr><td> Total loss at 24 months</td><td>&#8211;0.19 (&#8211;0.23 to 0.04)</td><td>&#8211;0.26 (&#8211;0.37 to &#8211;0.15)</td><td>&#8211;0.09 (&#8211;0.13 to 0.05)</td><td>&#8211;0.08 (&#8211;0.12 to 0.04</td></tr><tr><td colspan="5">Trilogy</td></tr><tr><td> 0&#8211;12</td><td>&#8211;0.16 (&#8211;0.32 to 0.01)</td><td>&#8211;0.25 (&#8211;0.44 to &#8211;0.06)</td><td>&#8211;0.10 (&#8211;0.28 to 0.07)</td><td>&#8211;0.10 (&#8211;0.24 to 0.04)</td></tr><tr><td> 12&#8211;24</td><td>&#8211;0.05 (&#8211;0.18 to 0.07)</td><td>&#8211;0.04 (&#8211;0.14 to 0.06)</td><td>&#8211;0.01 (&#8211;0.10 to 0.08)</td><td>&#8211;0.01 (&#8211;0.08 to 0.07)</td></tr><tr><td> Total loss at 24 months</td><td>&#8211;0.29 (&#8211;0.52 to &#8211;0.06)</td><td>&#8211;0.33 (&#8211;0.55 to &#8211;0.12)</td><td>&#8211;0.21 (&#8211;0.42 to 0.01)</td><td>&#8211;0.13 (&#8211;0.31 to 0.04)</td></tr></table>
d6fc0ba92d229512af81bbbf1091cfbb78caff6d499f57d6483b64c424a41bb6.png
complex
<table><tr><td></td><td colspan="2">Group A</td><td colspan="2">Group B</td><td></td></tr><tr><td></td><td colspan="2">6&#8211;8 years (<i>n</i> = 11)</td><td colspan="2">9&#8211;10 years (<i>n</i> = 17)</td><td rowspan="2"><i>P</i> value</td></tr><tr><td></td><td>median</td><td>range</td><td>median</td><td>range</td></tr><tr><td>Pelvis X</td><td>18.2</td><td>12.5&#8211;24.9</td><td>19.5</td><td>7.0&#8211;28.6</td><td>0.495</td></tr><tr><td>Pelvis Y</td><td>6.0</td><td>3.4&#8211;8.6</td><td>5.7</td><td>2.6&#8211;9.4</td><td>0.944</td></tr><tr><td>Pelvis Z</td><td>6.6</td><td>4.0&#8211;11.9</td><td>8.1</td><td>3.4&#8211;11.7</td><td>0.249</td></tr><tr><td>Hip X</td><td>43.6</td><td>41.8&#8211;51.5</td><td>46.2</td><td>35.2&#8211;57.6</td><td>0.196</td></tr><tr><td>Hip Y</td><td>7.2</td><td>4.5&#8211;11.0</td><td>8.4</td><td>4.8&#8211;11.1</td><td>0.438</td></tr><tr><td>Hip Z</td><td>2.5</td><td>&#8722;5.1&#8211;10.0</td><td>0.01</td><td>&#8722;9.7&#8211;5.8</td><td>0.115</td></tr><tr><td>Knee X</td><td>65.0</td><td>54.7&#8211;71.3</td><td>64.8</td><td>50.6&#8211;70.5</td><td>0.906</td></tr><tr><td>Knee Y</td><td>4.9</td><td>&#8722;3.1&#8211;11.8</td><td>2.6</td><td>&#8722;2.5&#8211;10.6</td><td>0.312</td></tr><tr><td>Knee Z</td><td>6.8</td><td>&#8722;0.1&#8211;13.2</td><td>5.4</td><td>&#8722;8.9&#8211;21.5</td><td>0.384</td></tr><tr><td>Ankle X</td><td>16.5</td><td>12.4&#8211;20.5</td><td>16.4</td><td>6.6&#8211;23.1</td><td>0.557</td></tr><tr><td>Foot Progression Z</td><td>&#8722;1.8</td><td>&#8722;17.8&#8211;4.8</td><td>&#8722;4.1</td><td>&#8722;18.7&#8211;5.5</td><td>0.525</td></tr></table>
a838176a8382dfeaef0b6b7220b7a321746b2fe1888393b97f2de964deb0e54d.png
simple
<table><tr><td>Simulation Results</td><td>Yeast 5</td><td>Yeast 6</td></tr><tr><td>Auxotroph-inducing genes</td><td>92</td><td>93</td></tr><tr><td>Correct auxotrophy predictions</td><td>57</td><td>64</td></tr><tr><td>Mutant incorrectly predicted to be viable in minimal medium</td><td>32</td><td>26</td></tr><tr><td>Mutant incorrectly predicted to be inviable in supplemented medium</td><td>3</td><td>3</td></tr></table>
6880acc786d2989f4499d641db3f010f71c8f6a3f66724cfb58c3b4ccf2d2890.png
complex
<table><tr><td></td><td colspan="3">Group C</td><td colspan="3">Group B</td></tr><tr><td>Subgroups</td><td>Normotensive(<i>n</i> = 41)</td><td>Treated HT(<i>n</i> = 7)</td><td>Untreated HT(<i>n</i> = 7)</td><td>Normotensive(<i>n</i> = 41)</td><td>Treated HT(<i>n</i> = 7)</td><td>Untreated HT(<i>n</i> = 4)</td></tr><tr><td>Additional Propofol</td><td>22 (55 %)</td><td>2 (29 %)</td><td>4 (57 %)</td><td>24 (59 %)</td><td>0 (0 %)</td><td>1 (25 %)</td></tr><tr><td colspan="7">Adverse Events</td></tr><tr><td> HR &lt; 50 bpm</td><td>3 (8 %)</td><td>1 (14 %)</td><td>2 (29 %)</td><td>3 (7 %)</td><td>2 (29 %)</td><td>0 (0 %)</td></tr><tr><td> SBP &lt; 70 mmHg</td><td>8 (20 %)</td><td>2 (29 %)</td><td>0 (0 %)</td><td>9 (22 %)</td><td>2 (29 %)</td><td>0 (0 %)</td></tr><tr><td> Use of Ephedrine</td><td>8 (20 %)</td><td>2 (29 %)</td><td>0 (0 %)</td><td>4 (10 %)</td><td>2 (29 %)</td><td>0 (0 %)</td></tr></table>
6288801ae9ebc7debebf85601cc88d039f643d96ba49f1c42431d9b5977ed83a.png
complex
<table><tr><td rowspan="2">Variables</td><td colspan="2">Univariate<sup>a</sup></td><td colspan="2">Multivariate<sup>a</sup></td></tr><tr><td>HR (95 % CI)</td><td><i>P</i> value</td><td>HR (95 % CI)</td><td><i>P</i> value</td></tr><tr><td colspan="5">Baseline characteristics</td></tr><tr><td>Age &lt;70 y (vs. &#8805;70 y)</td><td>0.749 (0.343&#8211;1.429)</td><td>0.380</td><td></td><td></td></tr><tr><td>Sex, male (vs. female)</td><td>0.634 (0.307&#8211;1.308)</td><td>0.217</td><td></td><td></td></tr><tr><td>HCV infection (vs. other etiology)</td><td>1.796 (0.964&#8211;3.348)</td><td>0.065</td><td></td><td></td></tr><tr><td>Child Pugh = 5 (vs. &#8805;6)</td><td>0.511 (0.271&#8211;0.962)</td><td>0.038</td><td></td><td></td></tr><tr><td>TMN stage III (vs. IV)</td><td>0.672 (0.357&#8211;1.264)</td><td>0.218</td><td></td><td></td></tr><tr><td>Vascular invasion &#8211; (vs. +)</td><td>0.355 (0.178&#8211;0.710)</td><td>0.003</td><td>0.382 (0.186&#8211;0.786)</td><td>0.009</td></tr><tr><td>Tumor size &lt;50 mm (vs. &#8805;50 mm)</td><td>0.777 (0.412&#8211;1.466)</td><td>0.432</td><td></td><td></td></tr><tr><td>Previous curative therapy: Yes (vs. No)</td><td>0.433 (0.226&#8211;0.829)</td><td>0.012</td><td></td><td></td></tr><tr><td>AFP &lt;100 (vs. &#8805;100)</td><td>1.048 (0.561&#8211;1.961)</td><td>0.954</td><td></td><td></td></tr><tr><td>DCP &lt;1000 (vs. &#8805;1000)</td><td>0.473 (0.509&#8211;0.912)</td><td>0.025</td><td>0.509 (0.261&#8211;0.993)</td><td>0.048</td></tr><tr><td>Initial dose of sorafenib 800 mg (vs. &lt;800 mg)</td><td>0.744 (0.388&#8211;1.426)</td><td>0.373</td><td></td><td></td></tr><tr><td colspan="5">HRQOL domain scores &#8805;40:<sup>b</sup></td></tr><tr><td>Physical functioning</td><td>0.956 (0.509&#8211;1.799)</td><td>0.889</td><td></td><td></td></tr><tr><td>Role physical</td><td>0.771 (0.416&#8211;1.429)</td><td>0.408</td><td></td><td></td></tr><tr><td>Bodily pain</td><td>1.582 (0.728&#8211;3.436)</td><td>0.247</td><td></td><td></td></tr><tr><td>General health</td><td>1.034 (0.516&#8211;2.070)</td><td>0.926</td><td></td><td></td></tr><tr><td>Vitality</td><td>1.534 (0.631&#8211;3.731)</td><td>0.346</td><td></td><td></td></tr><tr><td>Social functioning</td><td>0.395 (0.185&#8211;0.840)</td><td>0.016</td><td>0.452 (0.206&#8211;0.995)</td><td>0.049</td></tr><tr><td>Role emotional</td><td>0.898 (0.455&#8211;1.770)</td><td>0.755</td><td></td><td></td></tr><tr><td>Mental health</td><td>0.833 (0.379&#8211;1.828)</td><td>0.649</td><td></td><td></td></tr></table>
236061c79ffbc38b328ed065c3528f3d28410135e251d379b3bbf6da7e0e9136.png
simple
<table><tr><td>Subgroups</td><td>n</td><td>Cases of the grade of tracheal intubation conditions (1/2/3/4)</td><td>Cases of the anaphylaxis score (0/1/2/3)</td><td>Duration of surgery (min)</td></tr><tr><td>Group 1</td><td>39</td><td>29/10/0/0</td><td>32/7/0/0</td><td>69 &#177; 34</td></tr><tr><td>Group 2</td><td>37</td><td>29/8/0/0</td><td>35/2/0/0</td><td>75 &#177; 40</td></tr><tr><td>Group 3</td><td>39</td><td>37/2/0/0</td><td>35/2/2/0</td><td>76 &#177; 40</td></tr><tr><td>Group 4</td><td>40</td><td>31/9/0/0</td><td>38/2/0/0</td><td>67 &#177; 33</td></tr></table>
4cb8ec2b1f3a483911f22758fff18c2b04f2ee66d5fed2eb550b3c1092a987e4.png
simple
<table><tr><td>Demographic Characteristics</td><td>TOTAL</td><td>%</td></tr><tr><td>Female</td><td>15</td><td>75%</td></tr><tr><td>Race</td><td></td><td></td></tr><tr><td> White</td><td>15</td><td>75%</td></tr><tr><td> Black</td><td>4</td><td>20%</td></tr><tr><td> Asian</td><td>1</td><td>5%</td></tr><tr><td>Age</td><td></td><td></td></tr><tr><td> &#8804; 30</td><td>4</td><td>20%</td></tr><tr><td> 31&#8211;40</td><td>0</td><td>0%</td></tr><tr><td> 41&#8211;50</td><td>8</td><td>40%</td></tr><tr><td> 51&#8211;60</td><td>5</td><td>25%</td></tr><tr><td> 61&#8211;70</td><td>2</td><td>10%</td></tr><tr><td> &#8805; 71</td><td>1</td><td>5%</td></tr><tr><td>Education</td><td></td><td></td></tr><tr><td> Some or graduate of high school</td><td>10</td><td>50%</td></tr><tr><td> Some college</td><td>5</td><td>25%</td></tr><tr><td> College graduate</td><td>1</td><td>5%</td></tr><tr><td> Post graduate education</td><td>4</td><td>20%</td></tr><tr><td>Have access to e-mail &amp; Internet</td><td>19</td><td>95%</td></tr><tr><td>Location of frequent access to e-mail &amp; Internet</td><td></td><td></td></tr><tr><td> Home</td><td>9</td><td>45%</td></tr><tr><td> Library</td><td>4</td><td>20%</td></tr><tr><td> Multiple sites</td><td>5</td><td>25%</td></tr></table>
f069b52cc2fe1db61c77941dc1bfb5b21d14bbd821dac229479c2a34dd96c4f5.png
complex
<table><tr><td></td><td></td><td colspan="2">Using allopurinol</td></tr><tr><td>Factor</td><td>Frequency (%)</td><td>No (%)</td><td>Yes (%)</td></tr><tr><td>Age Mean (SD)</td><td>65.6 (12.5)</td><td>65.1 (13.4)</td><td>65.9 (11.6)</td></tr><tr><td>Gender (Male %)</td><td>990 (83.6)</td><td>390 (79.6)</td><td>544 (86.4)</td></tr><tr><td colspan="4">Alcohol Consumption</td></tr><tr><td> Never</td><td>113 (9.7)</td><td>50 (10.4)</td><td>56 (9.0)</td></tr><tr><td> Occasionally</td><td>155 (13.3)</td><td>63 (13.1)</td><td>86 (13.8)</td></tr><tr><td> 1&#8211;3 times per month</td><td>109 (9.3)</td><td>47 (9.8)</td><td>57 (9.0)</td></tr><tr><td> 1&#8211;2 times per week</td><td>254 (21.8)</td><td>110 (22.9)</td><td>129 (20.6)</td></tr><tr><td> 3&#8211;4 times per week</td><td>263 (22.5)</td><td>102 (21.3)</td><td>148 (23.7)</td></tr><tr><td> Daily</td><td>273 (23.4)</td><td>108 (22.5)</td><td>149 (23.8)</td></tr><tr><td colspan="4">Body Mass Index</td></tr><tr><td> Normal (&lt;25 kg/m<sup>2</sup>)</td><td>371 (31.3)</td><td>168 (34.3)</td><td>178 (28.2)</td></tr><tr><td> Overweight/obese (&#8805;25 kg/m<sup>2</sup>)</td><td>813 (68.7)</td><td>322 (65.7)</td><td>452 (71.8)</td></tr><tr><td colspan="4">Neighbourhood Deprivation Status</td></tr><tr><td> 20 % least deprived</td><td>410 (34.6)</td><td>174 (35.5)</td><td>214 (34.0)</td></tr><tr><td> Mid-deprived</td><td>405 (34.2)</td><td>160 (32.7)</td><td>228 (36.2)</td></tr><tr><td> 20 % most deprived</td><td>369 (31.2)</td><td>156 (31.8)</td><td>188 (29.8)</td></tr><tr><td>Depression (PHQ-9)</td><td>131 (11.1)</td><td>46 (11.0)</td><td>76 (13.4)</td></tr><tr><td>Anxiety (GAD-7)</td><td>109 (10.0)</td><td>42 (9.3)</td><td>59 (10.0)</td></tr><tr><td>Type II Diabetes Mellitus</td><td>205 (17.3)</td><td>60 (12.2)</td><td>138 (21.9)</td></tr><tr><td>Stroke</td><td>37 (3.1)</td><td>12 (2.5)</td><td>24 (3.8)</td></tr><tr><td>Hypertension</td><td>731 (61.7)</td><td>274 (55.9)</td><td>414 (65.7)</td></tr><tr><td>Transient Ischaemic Attack</td><td>62 (5.2)</td><td>24 (4.9)</td><td>34 (5.4)</td></tr><tr><td>Hyperlipidaemia</td><td>508 (42.9)</td><td>190 (38.8)</td><td>291 (46.2)</td></tr><tr><td>Kidney Failure</td><td>56 (4.7)</td><td>18 (3.7)</td><td>31 (4.9)</td></tr><tr><td>Myocardial Infarction</td><td>119 (10.1)</td><td>44 (9.0)</td><td>67 (10.6)</td></tr><tr><td>Kidney Stones</td><td>81 (6.8)</td><td>23 (4.7)</td><td>51 (8.1)</td></tr><tr><td>Angina</td><td>147 (12.4)</td><td>49 (10.0)</td><td>88 (14.0)</td></tr></table>
f28b1745581ddc6333f0b06cdc9c279e65fdf656e31ad893b6f7fa3ad524a594.png
simple
<table><tr><td>MiR</td><td>Parametric p-value</td><td>FDR</td><td>Permutation p-value</td><td>Geom mean of intensities in class 1</td><td>Geom mean of intensities in class 2</td><td>Geom mean of intensities in class 3</td><td>Geom mean of intensities in class 4</td></tr><tr><td>hsa-miR-204-4373094</td><td>0.00004</td><td>0.02784</td><td>&lt; 1e-07</td><td>15.74986</td><td>11.70222</td><td>14.82001</td><td>6.94659</td></tr><tr><td>hsa-miR-30aSTAR-4373062</td><td>0.00035</td><td>0.11658</td><td>0.00010</td><td>7.67985</td><td>6.27768</td><td>7.25131</td><td>6.95430</td></tr></table>
b1aeac26679b03209d72b8bdc3d7c7e4de71dcc23f8b542435b2d88beaa48f64.png
simple
<table><tr><td>Test</td><td>TAA/TAD (%)</td><td>Control (%)</td><td>P-value</td></tr><tr><td>White Blood Cell</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>93 (70)</td><td>103 (77)</td><td>0.29</td></tr><tr><td>Low (&lt;3 million cells/mcL)</td><td>8 (6)</td><td>9 (7)</td><td>1</td></tr><tr><td>High (&gt;12 million cells/mcL)</td><td>31 (23)</td><td>22 (16)</td><td>0.20</td></tr><tr><td>Hemoglobin</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>80 (60)</td><td>81 (60)</td><td>1</td></tr><tr><td>Low (&lt;9 grams/dL)</td><td>47 (35)</td><td>47 (35)</td><td>1</td></tr><tr><td>High (&gt;15 grams/dL)</td><td>7 (5)</td><td>6 (4)</td><td>1</td></tr><tr><td>Hematocrit</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>75 (56)</td><td>78 (58)</td><td>0.81</td></tr><tr><td>Low (&lt;27%)</td><td>51 (38)</td><td>49 (37)</td><td>0.89</td></tr><tr><td>High (&gt;55%)</td><td>8 (6)</td><td>7 (5)</td><td>1</td></tr><tr><td>Blood Urea Nitrogen</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>45 (34)</td><td>69 (51)</td><td>&lt;.0001*</td></tr><tr><td>Low</td><td>2 (2)</td><td>1 (1)</td><td>1</td></tr><tr><td>High</td><td>85 (64)</td><td>64 (48)</td><td>&lt;.0001*</td></tr><tr><td>Creatinine</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>71 (56)</td><td>80 (62)</td><td>0.40</td></tr><tr><td>Elevated (&gt;35 mg/dL)</td><td>55 (44)</td><td>49 (38)</td><td>0.47</td></tr><tr><td>Lactate</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>6 (60)</td><td>7 (64)</td><td>0.65</td></tr><tr><td>Elevated (&gt;2.5 mEq/L)</td><td>4 (40)</td><td>4 (36)</td><td>0.89</td></tr><tr><td>INR</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>76 (60)</td><td>75 (81)</td><td> </td></tr><tr><td>Elevated (&gt;1.5)</td><td>51 (40)</td><td>18 (19)</td><td>0.0017*</td></tr><tr><td>D-Dimer</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>1 (20)</td><td>7 (88)</td><td>0.06</td></tr><tr><td>Elevated (&gt; 250 ng/ml)</td><td>4 (80)</td><td>1 (13)</td><td>0.06</td></tr><tr><td>Troponin</td><td> </td><td> </td><td> </td></tr><tr><td>Normal</td><td>53 (82)</td><td>80 (66)</td><td>0.04</td></tr><tr><td>Elevated (&gt;0.3 ng/mL)</td><td>12 (18)</td><td>41 (34)</td><td>0.04*</td></tr></table>
c9d894ccb57fd873bb5b5b4cf479024ea4f7715feee7e22eda8b6e3c4ec0cf8c.png
simple
<table><tr><td></td><td>Count</td><td>%</td></tr><tr><td>He/she used to work but is currently unemployed</td><td>0</td><td>0.00</td></tr><tr><td>He/she never worked and neither does now</td><td>0</td><td>0.00</td></tr><tr><td>Clerk (civil or private)</td><td>338</td><td>63.41</td></tr><tr><td>Free professional (tradesman, craftsman)</td><td>62</td><td>11.63</td></tr><tr><td>Doctor, lawyer, engineer, priest, teacher, etc.</td><td>75</td><td>14.07</td></tr><tr><td>Student (college or university)</td><td>12</td><td>2.25</td></tr><tr><td>Blue collar worker (construction worker, farmer)</td><td>26</td><td>4.88</td></tr><tr><td>Housewife</td><td>20</td><td>3.75</td></tr><tr><td>Total</td><td>533</td><td>100.00</td></tr></table>
8f9e8870f4cd5f6bb1f4e98c06cfd46e45330158180592ad0baaba6edecb1f80.png
simple
<table><tr><td>Variables</td><td>N (%)</td><td>Prevalence of Internet use (%)<sup>a</sup></td><td>Total scores<sup>b</sup></td><td>Prevalence of AIA (%)<sup>c,d</sup></td></tr><tr><td>Paternal education (missing 23)</td><td> </td><td><i>p</i> &lt;0.001</td><td><i>p</i> &lt;0.001</td><td><i>p =</i>0.01</td></tr><tr><td>Illiteracy and elementary</td><td>101 (2.0%)</td><td>84.2% (85/101)</td><td>112.3 &#177; 53.7</td><td>9.9% (10/101)</td></tr><tr><td>Junior high school</td><td>1115 (21.8%)</td><td>92.8% (1035/1115)</td><td>116.9 &#177; 43.3</td><td>8.7% (97/1115)</td></tr><tr><td>Senior high school</td><td>2362 (46.1%)</td><td>94.9% (2242/2362)</td><td>122.8 &#177; 39.1</td><td>10.0% (235/2362)</td></tr><tr><td>University-level and beyond</td><td>1521 (29.7%)</td><td>93.6% (1424/1521)</td><td>117.4 &#177; 40.5</td><td>6.8% (104/1521)</td></tr><tr><td>Maternal education (missing 26)</td><td> </td><td><i>p =</i>0.002</td><td><i>p &lt;</i>0.001</td><td><i>p =</i>0.001</td></tr><tr><td>Illiteracy and elementary</td><td>147 (2.9%)</td><td>91.2% (134/147)</td><td>110.8 &#177; 44.0</td><td>4.1% (6/147)</td></tr><tr><td>Junior high school</td><td>1215 (23.7%)</td><td>92.2% (1120/1215)</td><td>116.4 &#177; 43.6</td><td>8.7% (106/1215)</td></tr><tr><td>Senior high school</td><td>2327 (45.4%)</td><td>94.8% (2206/2327)</td><td>123.2 &#177; 39.5</td><td>10.3% (239/2327)</td></tr><tr><td>University-level and beyond</td><td>1407 (27.5%)</td><td>94.0% (1323/1407)</td><td>117.6 &#177; 40.0</td><td>6.9% (97/1407)</td></tr><tr><td>Family structure (missing 0)</td><td> </td><td><i>p</i> =0.22</td><td><i>p</i> =0.01</td><td><i>p</i> =0.01</td></tr><tr><td>Nuclear family</td><td>3380 (66.0%)</td><td>93.5% (3158/3380)</td><td>118.9 &#177; 41.2</td><td>8.5% (288/3380)</td></tr><tr><td>Three-generation family</td><td>1069 (20.9%)</td><td>95.0% (1016/1069)</td><td>118.9 &#177; 38.9</td><td>7.5% (80/1069)</td></tr><tr><td>Single parent family</td><td>357 (7.0%)</td><td>93.6% (334/357)</td><td>124.3 &#177; 44.0</td><td>13.2% (47/357)</td></tr><tr><td>Left-behind adolescents</td><td>181 (3.5%)</td><td>93.9% (170/181)</td><td>124.7 &#177; 43.5</td><td>12.2% (22/181)</td></tr><tr><td>Weekend parents</td><td>135 (2.6%)</td><td>96.3% (130/135)</td><td>126.8 &#177; 35.1</td><td>9.6% (13/135)</td></tr><tr><td>Parental marriage (missing 4)</td><td> </td><td><i>p</i> =0.23</td><td><i>p</i> =0.003</td><td><i>p</i> =0.004</td></tr><tr><td>Married &amp; together</td><td>4477 (87.4%)</td><td>93.9% (4202/4477)</td><td>119.0 &#177; 40.5</td><td>8.3% (370/4477)</td></tr><tr><td>Married-but-separated</td><td>81 (1.6%)</td><td>93.8% (76/81)</td><td>132.5 &#177; 44.2</td><td>17.3% (14/81)</td></tr><tr><td>Divorced</td><td>360 (7.0%)</td><td>93.6% (337/360)</td><td>124.2 &#177; 43.5</td><td>12.2% (44/360)</td></tr><tr><td>Widowed</td><td>86 (1.7%)</td><td>90.7% (78/86)</td><td>117.5 &#177; 47.1</td><td>10.5% (9/86)</td></tr><tr><td>Remarried</td><td>114 (2.2%)</td><td>97.4% (111/114)</td><td>125.6 &#177; 35.9</td><td>11.4% (13/114)</td></tr><tr><td>Commuter students or not (missing 13)</td><td> </td><td><i>p</i> =0.03</td><td><i>p</i> =0.002</td><td><i>p</i> =0.67</td></tr><tr><td>Resident students</td><td>451 (8.8%)</td><td>96.0% (433/451)</td><td>125.2 &#177; 35.6</td><td>9.5% (43/451)</td></tr><tr><td>Commuter students</td><td>4668 (91.2%)</td><td>93.7% (4372/4668)</td><td>119.2 &#177; 41.3</td><td>8.7% (407/4668)</td></tr><tr><td>Only child (missing 12)</td><td> </td><td><i>p =</i>0.34</td><td><i>p =</i>0.21</td><td><i>p =</i>0.56</td></tr><tr><td>Yes</td><td>4658 (90.9%)</td><td>94.0% (4377/4658)</td><td>119.9 &#177; 40.8</td><td>8.9% (413/4658)</td></tr><tr><td>No</td><td>452 (8.8%)</td><td>92.9% (420/452)</td><td>117.4 &#177; 42.0</td><td>8.0% (36/452)</td></tr><tr><td>Family housing (missing 18)</td><td> </td><td><i>p</i> &lt;0.001</td><td><i>p</i> =0.01</td><td><i>p</i> =0.27</td></tr><tr><td>Own</td><td>4724 (92.2%)</td><td>94.3% (4455/4724)</td><td>120.1 &#177; 40.3</td><td>9.0% (423/4724)</td></tr><tr><td>Rent</td><td>380 (7.4%)</td><td>89.0% (338/380)</td><td>114.4 &#177; 46.9</td><td>6.8% (26/380)</td></tr><tr><td>Having computers at home (missing 3)</td><td> </td><td><i>p</i> &lt;0.001</td><td><i>p</i> &lt;0.001</td><td><i>p</i> &lt;0.001</td></tr><tr><td>Yes</td><td>4359 (85.1%)</td><td>96.5% (4208/4359)</td><td>123.9 &#177; 36.4</td><td>9.7% (422/4359)</td></tr><tr><td>No</td><td>760 (14.8%)</td><td>78.6% (597/760)</td><td>95.2 &#177; 54.4</td><td>3.7% (28/760)</td></tr><tr><td>Having private bedroom (missing 9)</td><td> </td><td><i>p</i> &lt;0.001</td><td><i>p =</i>0.02</td><td><i>p =</i>0.32</td></tr><tr><td>Yes</td><td>4169 (81.4%)</td><td>94.5% (3940/4169)</td><td>120.3 &#177; 39.7</td><td>8.6% (360/4169)</td></tr><tr><td>No</td><td>944 (18.4%)</td><td>91.1% (860/944)</td><td>116.8 &#177; 45.6</td><td>9.3% (88/944)</td></tr></table>
f2d9d750017e9a50421c8de909d705203eb8fa763ddb698ae3312a40e8f664ef.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">Mean &#177; SD before and after treatment with</td></tr><tr><td>PZQ</td><td>ARA</td><td>PZQ + ARA</td></tr><tr><td>Children</td><td>84</td><td>88</td><td>83</td></tr><tr><td colspan="4">Parameter</td></tr><tr><td colspan="4"> PT (seconds)</td></tr><tr><td>Before</td><td>14.43 &#177; 0.96</td><td>14.25 &#177; 0.75</td><td>14.31 &#177; 0.71</td></tr><tr><td>After</td><td>13.98 &#177; 0.61</td><td>13.99 &#177; 0.52</td><td>14.01 &#177; 0.60</td></tr><tr><td><i>P</i> value</td><td>0.0005</td><td>0.0122</td><td>0.0030</td></tr><tr><td colspan="4"> CT (seconds)</td></tr><tr><td>Before</td><td>13.19 &#177; 0.02</td><td>13.19 &#177; 0.02</td><td>13.20 &#177; 0.36</td></tr><tr><td>After</td><td>13.09 &#177; 0.01</td><td>13.10 &#177; 1.04</td><td>13.10 &#177; 0.64</td></tr><tr><td><i>P</i> value</td><td>&lt; 0.0001</td><td>&lt; 0.0001</td><td>NS</td></tr><tr><td colspan="4"> PT concentration (%)</td></tr><tr><td>Before</td><td>84.62 &#177; 9.89</td><td>86.18 &#177; 8.45</td><td>85.49 &#177; 8.31</td></tr><tr><td>After</td><td>87.50 &#177; 7.82</td><td>87.32 &#177; 8.04</td><td>87.03 &#177; 7.71</td></tr><tr><td><i>P</i> value</td><td>0.0375</td><td>NS</td><td>NS</td></tr><tr><td colspan="4"> INR</td></tr><tr><td>Before</td><td>1.11 &#177; 0.09</td><td>1.10 &#177; 0.07</td><td>1.11 &#177; 0.07</td></tr><tr><td>After</td><td>1.08 &#177; 0.06 (NS)</td><td>1.08 &#177; 0.06 (NS)</td><td>1.09 &#177; 0.06 (0.035)</td></tr><tr><td colspan="4"> PT/INR</td></tr><tr><td>Before</td><td>1.09 &#177; 0.07</td><td>1.07 &#177; 0.05</td><td>1.08 &#177; 0.05</td></tr><tr><td>After</td><td>1.06 &#177; 0.04</td><td>1.10 &#177; 0.31</td><td>1.10 &#177; 0.32</td></tr><tr><td><i>P</i> value</td><td>0.0163</td><td>NS</td><td>NS</td></tr><tr><td colspan="4"> PTT (seconds)</td></tr><tr><td>Before</td><td>34.38 &#177; 8.10</td><td>33.10 &#177; 4.21</td><td>33.15 &#177; 4.87</td></tr><tr><td>After</td><td>33.81 &#177; 4.57 (NS)</td><td>33.50 &#177; 5.19 (NS)</td><td>33.48 &#177; 5.19 (NS)</td></tr></table>
9e32a35158626c24a7f9c17a80c360ee7a866599257474c00580b028bb472b28.png
complex
<table><tr><td></td><td colspan="2">PLK1</td><td colspan="2">PAK4</td><td colspan="2">PAK5</td><td colspan="2">PAK6</td></tr><tr><td></td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td><td>SSS</td><td>GAP</td></tr><tr><td>PLK1</td><td>0.000</td><td>100</td><td>0.981</td><td>39.688</td><td>0.976</td><td>37.813</td><td>0.969</td><td>39.264</td></tr><tr><td>PAK4</td><td>0.981</td><td>39.688</td><td>0.000</td><td>100</td><td>0.681</td><td>69.898</td><td>0.845</td><td>63.776</td></tr><tr><td>PAK5</td><td>0.976</td><td>37.813</td><td>0.681</td><td>69.898</td><td>0.000</td><td>100</td><td>0.870</td><td>58.045</td></tr><tr><td>PAK6</td><td>0.969</td><td>39.264</td><td>0.845</td><td>63.776</td><td>0.870</td><td>58.045</td><td>0.000</td><td>100</td></tr></table>
1aa1585031b997a442f81191f82dee78094a186a444d500fabbf77630663a34e.png
simple
<table><tr><td> </td><td>Hazard ratio</td><td>95% confidence interval</td><td><i>p</i> value</td></tr><tr><td>Mean age<sup><i>&#8727;</i></sup></td><td>1.026</td><td>1.013&#8211;1.040</td><td>&lt;0.001</td></tr><tr><td>Country of birth, Nordic country</td><td>1.446</td><td>0.980&#8211;2.135</td><td>0.063</td></tr><tr><td>Chronic physical disease</td><td>1.025</td><td>0.789&#8211;1.332</td><td>0.851</td></tr><tr><td>Work for the last 3 yrs</td><td>0.781</td><td>0.588&#8211;1.038</td><td>0.088</td></tr><tr><td><i>Lifetime history of substance abuse (&gt;1 yr)</i></td><td> </td><td> </td><td> </td></tr><tr><td>Binge drinking</td><td>1.001</td><td>0.768&#8211;1.304</td><td>0.995</td></tr><tr><td>Heroin<sup><i>&#8727;</i></sup></td><td>1.737</td><td>1.261&#8211;2.393</td><td>0.001</td></tr><tr><td>Other opioids</td><td>0.938</td><td>0.655&#8211;1.345</td><td>0.729</td></tr><tr><td>Sedatives<sup><i>&#8727;</i></sup></td><td>1.404</td><td>1.026-1.923</td><td>0.034</td></tr><tr><td>Amphetamine<sup><i>&#8727;</i></sup></td><td>0.684</td><td>0.491&#8211;0.953</td><td>0.025</td></tr><tr><td>Cannabis</td><td>1.067</td><td>0.791&#8211;1.439</td><td>0.670</td></tr><tr><td>Injection drug use<sup><i>&#8727;</i></sup></td><td>1.430</td><td>1.013&#8211;2.018</td><td>0.042</td></tr><tr><td>Mean number of substances used, last 30 days</td><td>1.040</td><td>0.922&#8211;1.172</td><td>0.524</td></tr><tr><td><i>Lifetime history of psychiatric problems</i></td><td> </td><td> </td><td> </td></tr><tr><td>Hospitalization</td><td>1.099</td><td>0.784&#8211;1.541</td><td>0.583</td></tr><tr><td>Suicide attempt</td><td>1.136</td><td>0.839&#8211;1.539</td><td>0.410</td></tr></table>
7123cf308f247dbde38f3b1d735d14cf94b74128a654bc07ec8a12bbc61bb6ef.png
simple
<table><tr><td>Cardiometabolic disease outcome</td><td>Amount quintile 1</td><td>Amount quintile 2</td><td>Amount quintile 3</td><td>Amount quintile 4</td><td>Amount quintile 5</td><td><i>P</i>-trend</td></tr><tr><td>Odds ratio (95% CI)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Cardiometabolic</td><td>Referent</td><td>0.88 (0.76&#8211;1.03)</td><td>1.04 (0.88&#8211;1.21)</td><td>0.94 (0.82&#8211;1.06)</td><td>0.95 (0.82&#8211;1.11)</td><td>0.805</td></tr><tr><td> Cardiovascular</td><td>Referent</td><td>0.79 (0.65&#8211;0.97)</td><td>0.97 (0.78&#8211;1.21)</td><td>0.81 (0.67&#8211;0.99)</td><td>0.79 (0.64&#8211;0.97)</td><td>0.050</td></tr><tr><td> Coronary heart</td><td>Referent</td><td>0.84 (0.65&#8211;1.07)</td><td>0.90 (0.70&#8211;1.16)</td><td>0.80 (0.64&#8211;1.01)</td><td>0.75 (0.59&#8211;0.96)</td><td>0.026</td></tr><tr><td> Stroke</td><td>Referent</td><td>0.75 (0.55&#8211;1.02)</td><td>1.08 (0.82&#8211;1.43)</td><td>0.88 (0.70&#8211;1.11)</td><td>0.87 (0.67&#8211;1.12)</td><td>0.667</td></tr><tr><td> Diabetes</td><td>Referent</td><td>0.97 (0.82&#8211;1.14)</td><td>1.04 (0.87&#8211;1.25)</td><td>0.98 (0.85&#8211;1.13)</td><td>1.00 (0.86&#8211;1.17)</td><td>0.961</td></tr></table>
2467cea2ebd88e34eb0b80fac644b764a51dd512bc25d7e8aafe47c50838b15d.png
simple
<table><tr><td>Cluster ID</td><td>No. of sequences</td><td>Percentage of effective siRNAs (%)</td></tr><tr><td>C1</td><td>134</td><td>94</td></tr><tr><td>C2</td><td>150</td><td>70.7</td></tr><tr><td>C3</td><td>125</td><td>70.4</td></tr><tr><td>C4</td><td>147</td><td>61.9</td></tr><tr><td>C5</td><td>141</td><td>43.3</td></tr><tr><td>C6</td><td>158</td><td>32.3</td></tr><tr><td>C7</td><td>143</td><td>27.1</td></tr><tr><td>C8</td><td>148</td><td>8.1</td></tr></table>
5b2605e0acac303ad25e730289eab19d7608853a166eca1d036b6676f3aed78c.png
simple
<table><tr><td></td><td>No. Patients (%)</td><td>Methylation (%)</td><td><i>P</i></td></tr><tr><td>All patients </td><td>50 (100)</td><td>31( 62)</td><td></td></tr><tr><td> Male</td><td>42 ( 84)</td><td>27 (64)</td><td></td></tr><tr><td> Female</td><td>8 (16)</td><td>4 (50)</td><td>0.450</td></tr><tr><td>Site</td><td></td><td></td><td></td></tr><tr><td> Oral Cavity</td><td>22 (44)</td><td>13 (59)</td><td></td></tr><tr><td> Oropharynx</td><td> 5 (10)</td><td>4 (80)</td><td></td></tr><tr><td> Hypopharynx</td><td>6 (12)</td><td>3 (50)</td><td></td></tr><tr><td> Larynx </td><td>17 (34)</td><td>11 (65)</td><td>0.756</td></tr><tr><td>Tumor differentiation </td><td></td><td></td><td></td></tr><tr><td> Well differentiated</td><td>13 (26)</td><td>10 (76)</td><td></td></tr><tr><td> Mod. differentiated</td><td>30 (60)</td><td>19 (63)</td><td></td></tr><tr><td> Poorly differentiated</td><td> 5 (19)</td><td>4 (80)</td><td>0.649</td></tr><tr><td> n.a.</td><td> 2 ( 4)</td><td></td><td></td></tr><tr><td>Disease stage</td><td></td><td></td><td></td></tr><tr><td>I</td><td>4 ( 8)</td><td>3 (75)</td><td></td></tr><tr><td>II</td><td>7 (14)</td><td>5 (71)</td><td></td></tr><tr><td>III</td><td>13 (26)</td><td>8 (62)</td><td></td></tr><tr><td>IV</td><td>26 (52)</td><td>15 (57)</td><td>0.917</td></tr><tr><td>Median age (range), y</td><td>61.54 (38&#8211;84)</td><td></td><td></td></tr></table>
f95e31829130f0eb250596c789b2f739fff2d6943061f70339fe68f6dc09632c.png
simple
<table><tr><td>Method</td><td>Resnik</td><td>Relevance</td><td>Wang</td><td>NETSIM</td><td>NETSIM2</td></tr><tr><td>25%</td><td>0.07</td><td>0.15</td><td>0.17</td><td>0.12</td><td>0.002</td></tr><tr><td>50%</td><td>0.17</td><td>0.43</td><td>0.40</td><td>0.47</td><td>1.94</td></tr><tr><td>75%</td><td>0.42</td><td>1.03</td><td>0.91</td><td>1.19</td><td>3.75</td></tr></table>
5323677ce9e9a78d3679fdf3b1a9728be1da2c38afc4ee09e1eb4ea06dc87c1b.png
complex
<table><tr><td> </td><td colspan="3">Without DM (n = 334)</td><td colspan="3">With DM (n = 122)</td></tr><tr><td>Characteristics</td><td>VAT T1 (n = 111)</td><td>VAT T2 (n = 112)</td><td>VAT T3 (n = 111)</td><td>VAT T1 (n = 40)</td><td>VAT T2 (n = 41)</td><td>VAT T3 (n = 41)</td></tr><tr><td>Calcified plaque</td><td>1.7 &#177; 2.3</td><td>2.1 &#177; 2.7</td><td>3.0 &#177; 3.1*&#8224;</td><td>3.4 &#177; 3.4</td><td>3.3 &#177; 3.3</td><td>4.8 &#177; 3.7</td></tr><tr><td>Noncalcified plaque</td><td>0.7 &#177; 1.3</td><td>1.3 &#177; 1.6*</td><td>1.6 &#177; 2.0*</td><td>2.1 &#177; 2.2</td><td>2.0 &#177; 2.2</td><td>2.4 &#177; 2.1</td></tr><tr><td>Mixed plaque</td><td>0.5 &#177; 0.9</td><td>0.9 &#177; 1.2*</td><td>1.2 &#177; 1.7*</td><td>1.3 &#177; 1.6</td><td>1.3 &#177; 1.9</td><td>1.7 &#177; 1.8</td></tr><tr><td>Vulnerable plaque</td><td>0.2 &#177; 0.6</td><td>0.3 &#177; 0.5</td><td>0.3 &#177; 0.7*</td><td>0.6 &#177; 1.1</td><td>0.6 &#177; 1.0</td><td>0.5 &#177; 0.8</td></tr><tr><td>Significant stenosis</td><td>0.3 &#177; 0.7</td><td>0.3 &#177; 0.8</td><td>0.6 &#177; 1.3*&#8224;</td><td>0.6 &#177; 1.1</td><td>0.6 &#177; 1.2</td><td>0.8 &#177; 1.2</td></tr><tr><td>Coronary artery calcium score</td><td>177 (156)</td><td>207 (145)</td><td>307 (270)</td><td>461 (746)</td><td>380 (241)</td><td>495 (958)</td></tr></table>
1af6852f229bbcd9d07b5c0fed52bc497c857c18e472ad593bc85610806d25e6.png
simple
<table><tr><td></td><td>Grenoble (n = 232)</td><td>Montpellier (n = 128)</td><td>Paris (n = 272)</td><td>Total (n = 632)</td></tr><tr><td>Genotype, %</td><td></td><td></td><td></td><td></td></tr><tr><td>AA</td><td>16.8</td><td>21.9</td><td>15.4</td><td>17.3</td></tr><tr><td>AG</td><td>47.0</td><td>46.9</td><td>49.6</td><td>48.1</td></tr><tr><td>GG</td><td>36.2</td><td>31.3</td><td>34.9</td><td>34.7</td></tr><tr><td>Allele, %</td><td></td><td></td><td></td><td></td></tr><tr><td>A</td><td>40.3</td><td>45.3</td><td>40.3</td><td>41.3</td></tr><tr><td>G</td><td>59.7</td><td>54.7</td><td>59.7</td><td>58.7</td></tr></table>
4d9f9af861cc3546d23538fa3ddcf669fb9ca2caea203837656f0e84fb99f0b2.png
simple
<table><tr><td>Factor</td><td>Score</td></tr><tr><td>Vascular invasion</td><td></td></tr><tr><td> no</td><td>0</td></tr><tr><td> yes</td><td>2.6</td></tr><tr><td>BCLC stage</td><td></td></tr><tr><td> 0-A</td><td>0</td></tr><tr><td> B-C</td><td>1.3</td></tr><tr><td>MiR-145</td><td></td></tr><tr><td> negative</td><td>0</td></tr><tr><td> positive</td><td>1.3</td></tr><tr><td>MiR-31</td><td></td></tr><tr><td> negative</td><td>0</td></tr><tr><td> positive</td><td>1.7</td></tr><tr><td>MiR-92a</td><td></td></tr><tr><td> negative</td><td>0</td></tr><tr><td> positive</td><td>1</td></tr></table>
58005f8928fb67fd24a5bd42182e6f931a247f2f76c160989cadfe0111b366f1.png
simple
<table><tr><td></td><td>Exercise Sample</td><td>Physical Activity Sample</td></tr><tr><td>GoF</td><td>.412 [.436]</td><td>.554 [.564]</td></tr><tr><td>APC</td><td>.218; <i>p</i> &lt; .001 [.207; <i>p</i> &lt; .001]</td><td>.291; <i>p</i> &lt; .001 [.252; <i>p</i> &lt;. 001]</td></tr><tr><td>ARS</td><td>.195; <i>p</i> = .001 [.215; <i>p</i> &lt; .001]</td><td>.361; <i>p</i> &lt; .001 [.367; <i>p</i> &lt; .001]</td></tr><tr><td>AFVIF</td><td>1.242 [1.981]</td><td>1.468 [1.961]</td></tr></table>
8af71613ecb69d4c94e59ae07236a24faf7ec2bf7200c2e3bc6344688731df7f.png
simple
<table><tr><td>Time for data collection</td><td>Participants in the interviews</td></tr><tr><td>May&#8211;September 2013</td><td>Unit managers, n = 20Regional coordinators, n = 4Officials, n = 24</td></tr><tr><td>May&#8211;September 2014</td><td>Unit managers, n = 5Officials, n = 16</td></tr></table>